Exatecan derivatives, linker-payloads, and conjugates and thereof

Novel exatecan derivatives in ADCs utilize Sortase enzymes for stable, site-specific coupling, addressing instability and heterogeneity issues, enhancing efficacy and reducing toxicity in tumor treatment.

JP2024156884AActive Publication Date: 2024-11-06GENEQUANTUM HEALTHCARE (SUZHOU) CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024128609
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-16
Filing Date
2024-08-05
Publication Date
2024-11-06
Estimated Expiration
2042-11-15

AI Technical Summary

Technical Problem

Current antibody-drug conjugates (ADCs) face issues with unstable linkages between cytotoxic drugs and antibodies, leading to off-target toxicity and heterogeneity, limiting their clinical application due to the instability of sulfosuccinimide structures and non-specific chemical coupling reactions.

Method used

Development of exatecan derivatives with novel linker-payload conjugates using ligase-catalyzed enzymatic coupling, specifically employing Sortase enzymes to create stable and homogeneous ADCs by attaching exatecan derivatives to antibodies through precise, site-specific methods.

Benefits of technology

The new ADCs exhibit enhanced stability, reduced toxicity, and improved homogeneity, achieving higher efficacy and bystander killing effects with controlled drug release at tumor sites, thereby improving the therapeutic index.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156884000001_ABST
    Figure 2024156884000001_ABST
Patent Text Reader

Abstract

To provide a novel ADC with higher potency and lower toxicity.SOLUTION: The present disclosure relates to the biopharmaceutical field, in particular, exatecan derivatives, linker-payloads and conjugates thereof, and antibody-drug conjugates. An example thereof is a compound of formula (II) below, where A represents an antibody or an antigen binding fragment thereof, and P1 and P2 independently have a payload with an exatecan derivative structure.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of biopharmaceuticals, in particular to exatecan derivatives, their linker-payload and conjugates, antibody-drug conjugates, and the corresponding methods of preparation and use thereof. [Background technology]

[0002] In conventional tumor treatment, chemotherapy has become one of the main therapeutic strategies. However, off-target toxicity due to non-specific accumulation in normal tissues, short therapeutic window and low resistance limit the development of chemotherapy drugs. Since several decades, targeted therapy using monoclonal antibodies and polypeptides that bind to tumor cell surface specific markers shows less toxicity than chemotherapy. However, none of them has high efficacy in killing tumor cells.

[0003] In 1970, the first therapeutic strategy was discovered in which antibodies carrying toxins selectively kill target cells. Tumor-targeting drug conjugates mainly include ADCs, which generally couple antibodies that specifically recognize tumor cell surface antigens with chemical toxins via linkers, and the chemical toxins effectively kill tumor tissues. As of 2021, 120 ADCs are in clinical development.

[0004] Most cytotoxic payloads belong to two families: tubulin inhibitors (maytansinoids or auristatins) and DNA damaging agents (mainly calicheamicins), both of which are highly effective cytotoxic drugs and have been shown to be effective in the IC 50 Although the inhibitory concentration (IC) (inhibitory concentration that inhibits 50% of cells) is in the nanomolar and picomolar range, systemic administration is characterized by an unfavorable toxicity spectrum. By conjugating cytotoxic drugs to ADCs, they can be hidden in the blood and delivered directly to tumor cells, thereby significantly reducing the toxicity of these potent drugs. In general, drugs with good therapeutic indexes are not suitable for development as warheads and their IC 50It is believed that the amount is too low to function when delivered to tumor cells in a consistent amount.

[0005] Several ADC studies have offered promising new approaches by addressing either increasing the DAR or exploiting the bystander effect, allowing the use of less cytotoxic drugs as warheads.

[0006] To date, most of the developed warheads are tubulin inhibitors such as auristatins (e.g., monomethylauristatin E (MMAE) and monomethylauristatin F (MMAF)). Vedotin and enfortumab vedotin are both approved ADCs carrying the MMAE payload.

[0007] Topoisomerase I (TOP 1) inhibitors have been used as warheads in various ADCs. Sacituzumab govitecan carries SN-38, an active metabolite of irinotecan, as a warhead. Enhertu (fam-trastuzumab deruxtecan (DS8201a), also called T-Dxd) carries the exatecan derivative deruxtecan (Dxd) as a warhead (Patent Document 1) and has recently been approved for use in the treatment of breast cancer. On this basis, there is a strong need in the field for novel small molecule topoisomerase I inhibitors with higher activity, stability and physicochemical properties, whether used alone or as a component of an ADC.

[0008] However, on the one hand, Enhertu and other commercially available ADCs and most ADCs in clinical trials are produced by chemical coupling, using sulfosuccinimide structure (sulfosuccinimide linkage) to couple small molecule drugs to target antibodies or proteins. Sulfosuccinimide structure is formed by the reaction of sulfhydryl group with maleimide. Sulfosuccinimide linkage is unstable. In vivo, reverse Michael addition or exchange with other sulfhydryl groups causes cytotoxins to fall off from ADCs and induce off-target toxicity, thereby reducing safety and limiting clinical application. For example, Enhertu is highly effective, but causes interstitial lung disease in more than 10%, which limits its use in some patients. On the other hand, chemical coupling reaction is not site-specific, and the ADCs produced show a high degree of heterogeneity.

[0009] There remains a strong need for new ADCs with higher potency and lower toxicity. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] International Publication No. 2014057687 Summary of the Invention

[0011] In one aspect, the invention provides a compound of formula (I): [ka] Where: opSu is [ka] or [ka] and R 0 is C 1~10 is an alkyl group, n is any integer from 2 to 20; k1 and k2 are independently an integer from 1 to 7; i is an integer from 1 to 100; j is an integer from 1 to 100, P1 and P2 are independently a payload having the structure shown in formula (i'), [ka] Where: a is 0 or 1, p1 * Carbon atom with p2 attached * each carbon atom marked with is an asymmetric center, and said asymmetric center is in the S configuration, the R configuration or is racemized; L 1 is C 1~6 alkylene groups, unsubstituted or selected from halogen, -OH and and -NH2; M is -CH2-, -NH- or -O-; L 2 is C 1~3 is an alkylene group, R 1 and R 2 are each independently hydrogen, C 1~6 Alkyl groups, halogens and C 1~6 The alkoxy group is selected from the group consisting of aryl, ... and aryl groups.

[0012] In a second aspect, the present invention provides a conjugate having the structure shown in formula (II): [ka] Where: (A) is an antibody or an antigen-binding fragment thereof, said antibody or antigen-binding fragment thereof being preferably modified to modify (Gly) in the compound of formula (I). n Binding to the part, z is an integer from 1 to 20, preferably from 1 to 4, and particularly preferably 2; P1, P2, R 0, opSu, n, k1, k2, i and j are defined in formula (I). As stated above.

[0013] In a third aspect, the present invention provides a pharmaceutical composition comprising a conjugate of the present invention and at least one pharma- ceutically acceptable carrier.

[0014] In a fourth aspect, the present invention provides the use of a conjugate or a pharmaceutical composition of the invention in the manufacture of a medicament for treating a disease, said disease being a tumor or an autoimmune disease, preferably a tumor comprising HER2-positive tumor cells.

[0015] In a fifth aspect, the present invention provides a compound having the structure shown in formula (i): [ka] Where: a, p1 * Carbon atom with p2 * A carbon atom with L 1 , M, L 2 , R 1 and R 2 is as defined in formula (I).

[0016] In a sixth aspect, the present invention provides a compound of formula (1): [ka] where k is an integer from 1 to 7, preferably 1 or 3 or 5, in particular 5; P is a payload having the structure shown in formula (i′), where the structure shown in formula (i′) is as defined in formula (I). [Brief description of the drawings]

[0017] [Figure 1] FIG. 1 shows the efficacy of the conjugate in the HER2 highly expressing cell line SK-BR-3. [Diagram 2]FIG. 1 shows the efficacy of the conjugates in the HER2 highly expressing cell line NCI-N87. [Diagram 3] FIG. 1 shows efficacy of the conjugates in the HER2-negative cell line MDA-MB-468. [Figure 4] Figure 4 shows the efficacy of the conjugates in SK-BR-3 and MDA-MB-468 co-culture systems. Figure 4a shows the results of GFP fluorescence detection. Figure 4b shows the results of luciferase substrate chemiluminescence detection. In Figures 4a and 4b, from left to right are CH-2-589, CH-2-593, CH-2-518, LC1184(8) and LC302-2-4(4), respectively. [Diagram 5] FIG. 13 shows the efficacy of the conjugate in SK-BR-3 and MDA-MB-468 co-culture systems passing GFP fluorescence detection. [Figure 6] FIG. 13 shows the time course of the average tumor volume in SCID Beige mice JIS 1 CDX model administered with 5 mg / kg of the conjugate. [Figure 7] FIG. 1 shows the time course of the average tumor volume in BALB / c nude mice, Capan-1 CDX model, administered 5 mg / kg of the conjugate. [Figure 8] FIG. 1 shows the time course of the average tumor volume and body weight in BALB / c nude mice Capan-1 CDX model administered 5 mg / kg of the conjugate. [Figure 9] FIG. 1 shows the time course of mean tumor volume and body weight in BALB / c nude mice NCI-N 87 CDX model administered 5 mg / kg of the conjugate. [Figure 10] FIG. 1 shows the in vitro serum stability of the conjugate after incubation in human serum for 0, 24, 48 and 96 hours. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The technical contents of the present invention will be described below with reference to specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in the specification. The present invention can be implemented or applied in other different specific embodiments. Those skilled in the art can make various modifications and changes without departing from the spirit of the present invention.

[0019] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. The terminology used herein refers to the art commonly understood in the field and includes variations and equivalent substitutions obvious to those skilled in the art. The following terms are believed to be readily understood by those skilled in the art, but are intended to provide a more thorough understanding of the present invention. To clarify, the following definitions are provided: Trade names mentioned herein refer to the corresponding products or their active ingredients. All patents, patent applications and publications cited herein are hereby incorporated by reference.

[0020] When an amount, concentration, or other value or parameter is stated as a range, a preferred range, or an upper preferred value and a lower preferred value, this should be understood to specifically disclose all ranges formed from a pair of upper range or preferred value and lower range or preferred value, regardless of whether the ranges are disclosed individually. When a range of numerical values ​​is disclosed herein, unless otherwise stated, the range is intended to include its endpoints as well as all integers and fractions (decimals) within the range. For example, the expression "i is an integer from 1 to 20" means that i is any integer from 1 to 20, for example, i may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. Other similar expressions, such as j, k, and g, should be understood in the same manner.

[0021] Singular forms such as "a kind" and "the kind" include the plural unless the context clearly indicates otherwise. The terms "one or more kinds" or "at least one" can refer to 1, 2, 3, 4, 5, 6, 7, 8, 9 or more.

[0022] When used in conjunction with a variable numerical value, the term "approximately" or "about" typically means that the value of the variable, and all values ​​of the variable, are within experimental error (e.g., within a 95% confidence interval of the mean) or within ±10% of the particular value, or within a broader range.

[0023] The terms "preferably" or "optionally" mean that a subsequently described event may, but does not necessarily, occur, and such description includes circumstances in which the event or circumstance does or does not occur.

[0024] The terms "comprising," "including," "containing," and "having" are open-ended and do not exclude other unrecited elements, steps, or ingredients. The term "consisting of" excludes unrecited elements, steps, or ingredients. The term "consisting essentially of" means that the scope is limited to the specified elements, steps, or ingredients, along with any elements, steps, or ingredients that do not materially affect the basic and novel characteristics of the claimed subject matter. The term "comprising" should be understood to include the terms "consisting essentially of" and "consisting of."

[0025] As used herein, the term "antibody" is used in the broadest sense and includes, among others, complete monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity. Antibodies may be of any subtype (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass, and may be derived from any suitable species. In some embodiments, the antibody is of human or murine origin. The antibody may be a fully human antibody, a humanized antibody, or a chimeric antibody produced by recombinant methods.

[0026] As used herein, a monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific for a single antigenic site. The term "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method.

[0027] A complete or full-length antibody essentially comprises an antigen-binding variable region and a light chain constant region (CL) and a heavy chain constant region (CH), and may comprise CH1, CH2, CH3 and CH4 depending on the antibody subtype. The antigen-binding variable region (also called fragment variable region, Fv fragment) generally comprises a light chain variable region (V L ) and the heavy chain variable region (V H ). The constant region may be a constant region having a native sequence (e.g., a constant region having a human native sequence) or an amino acid sequence variant thereof. The variable region recognizes and interacts with a target antigen. The constant region can be recognized and interacted with by the immune system.

[0028] An antibody fragment may contain a portion of an intact antibody, preferably the antigen binding or variable region thereof. Examples of antibody fragments are Fab, Fab', F(ab'), V H and CH1 domain The term "Fab fragments" includes Fd fragments, Fv fragments, single domain antibody (dAb) fragments, and isolated complementarity determining regions (CDRs). Fab fragments are antibody fragments obtained by digestion of full-length immunoglobulins with papain, or fragments of the same structure produced, for example, by recombinant expression. Fab fragments are fragments of the light chain (V L and CL) and another chain, said other chain comprising: The variable region of the heavy chain (V H ) and one constant region of the heavy chain (CH1). The fragments are antibody fragments obtained by digestion of immunoglobulins with pepsin at pH 4.0-4.5, or fragments with the same structure produced, for example, by recombinant expression. The F(ab')2 fragment essentially contains two Fab fragments, each heavy chain portion containing some additional amino acids and a cysteine ​​forming a disulfide bond linking the two fragments. The Fab' fragment is a fragment containing one half of the F(ab')2 fragment (one heavy chain and one light chain). The antibody fragment may contain multiple chains linked, for example, by disulfide bonds and / or peptide linkers. Examples of antibody fragments further include single chain Fv (scFv), Fv, dsFv, diabodies, Fd and Fd' fragments, and other fragments including modified fragments. The antibody fragments generally contain at least or about 50 amino acids, and generally contain at least or about 200 amino acids. Antigen-binding fragments may include any antibody fragment that, when inserted into an antibody framework (e.g., by replacing the corresponding region), obtains an antibody that immunospecifically binds to an antigen.

[0029] The antibody of the present invention can be produced using techniques well known in the art, such as the following techniques or a combination thereof: recombinant techniques, phage display techniques, synthetic techniques or other techniques known in the art. For example, recombinant antibodies (or antibody analogues) can be expressed in a suitable culture system (e.g., E. Coli or mammalian cells). The manipulation can refer, for example, to the introduction of ligase-specific recognition sequences at their termini.

[0030] HER2 refers to human epidermal growth factor receptor-2, which belongs to the epidermal growth factor receptor (EGFR) tyrosine kinase family. In this application, the terms ErbB2 and HER2 have the same meaning and can be used interchangeably.

[0031] As used herein, the term "antibody-drug conjugate" is referred to as a "conjugate."

[0032] A small molecule compound refers to a molecule having a size equivalent to that of an organic molecule generally used in drugs. The term does not include biopolymers (e.g., proteins, nucleic acids, etc.), but includes low molecular weight peptides or their derivatives, such as dipeptides, tripeptides, tetrapeptides, pentapeptides, etc. In general, the molecular weight of a small molecule compound may be, for example, about 100 to about 2000 Da, about 200 to about 1000 Da, about 200 to about 900 Da, about 200 to about 800 Da, about 200 to about 700 Da, about 200 to about 600 Da, or about 200 to about 500 Da.

[0033] "Spacer" refers to a structure that is located between different structural modules and can separate the structural modules from the space. The definition of spacer does not limit whether it has a certain function, and does not limit whether it can be cleaved or degraded in vivo. Examples of spacers include, but are not limited to, amino acids and non-amino acid structures, and the non-amino acid structures may be, but are not limited to, amino acid derivatives or analogs. "Spacer sequence" refers to an amino acid sequence that serves as a spacer, examples of which include, but are not limited to, a sequence containing a single amino acid, a sequence containing two amino acids, such as GA, or, for example, GGGGS, GGGGSGGGGS, GGGGSGGGGSGGGGGS, etc. Since the self-immolative spacer is a covalent bond assembly, two chemical bonds are successively decomposed after the protective moiety in the precursor is activated, and the protective moiety (e.g., a cleavable sequence) is removed after activation, and a cascade-type decomposition reaction occurs to release smaller molecules according to the priority order. Examples of self-immolative spacers include, but are not limited to, PABC (p-benzyloxycarbonyl), acetals, heteroacetals, and combinations thereof.

[0034] The term "alkyl group" refers to a saturated aliphatic hydrocarbon group composed of carbon and hydrogen atoms and attached to the remainder of the molecule by a single bond. Alkyl groups include straight chain alkyl groups, branched chain alkyl groups, or cyclic alkyl groups (cycloalkyl groups) or partially cyclic alkyl groups (e.g., cycloalkyl group-straight chain alkyl group and cycloalkyl group-branched chain alkyl group). Alkyl groups may have 1 to 10 carbon atoms, and may be any of the following: 1-10 These are called alkyl groups, e.g., C 1~6 Alkyl group, C 1~4 Alkyl group, C 1~3 Alkyl group, C 1~2 Alkyl group, C3 alkyl group, C4 alkyl group, C 3~6It is an alkyl group. Non-limiting examples of straight chain alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, etc. Non-limiting examples of branched chain alkyl groups include, but are not limited to, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl, etc.

[0035] The terms "cyclic alkyl group" and "cycloalkyl group" have the same meaning and can be used interchangeably herein. Cycloalkyl groups can include monocyclic or polycyclic (e.g., having two or more fused rings) groups. In polycyclic cycloalkyl groups, two or more rings can be fused or bridged or spiro-fused. The ring-forming carbon atoms of a cycloalkyl group can be optionally substituted with oxo (i.e., C(O)). Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbon atoms (C(O)). 3~10 ) Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, and the like. In some embodiments, the cycloalkyl group is 3~6 is a monocyclic or bicyclic cycloalkyl group, preferably 3~6 Monocyclic cycloalkyl groups, especially cyclopropyl groups.

[0036] The term "partially cyclic" refers to the group containing one or more cyclic moieties and one or more non-cyclic (i.e., straight or branched) moieties. Partially cyclic alkyl groups may include cycloalkyl-straight chain alkyl groups and cycloalkyl-branched chain alkyl groups. Partially cyclic alkyl groups are groups having 4, 5, 6, 7, 8, 9, or 10 carbon atoms (C), including ring-forming carbon atoms and non-ring-forming carbon atoms. 3~10 Examples of partially cyclic alkyl groups include C 3~9 Cycloa Alkyl group - C1 alkyl group, C 3~8 Cycloalkyl group - C2 alkyl group, C 3~7 Cycloalkyl group - C3 linear alkyl group, C 3~6 Cycloalkyl group - C4 linear alkyl group, C 3~5 Cycloalkyl group - C5 linear alkyl group, C 3~4 Cycloalkyl group - C6 straight chain alkyl group, C3 Cycloalkyl group - C7 linear alkyl group, C 3~7 Cycloalkyl group - C3 branched alkyl group, C 3~6 Cycloalkyl group - C4 branched alkyl group, C 3~5 Cycloalkyl group - C5 branched alkyl group, C 3~4 These include, but are not limited to, cycloalkyl groups-C6 branched alkyl groups and C3 cycloalkyl groups-C7 branched alkyl groups. Partially cyclic alkyl groups are C 3~9 Cycloalkyl group -C1 alkyl group, preferably C 3~6 Cycloalkyl Group-C 1~2 Alkyl group, C 3~6 Cycloalkyl group - C1 alkyl group and more preferably, C 3~4 Cycloalkyl Group-C 1~2 Alkyl groups, especially C 3~4 Cycloalkyl groups are C1 alkyl groups, in particular cyclopropyl-methyl groups.

[0037] A divalent radical refers to a group obtained by removing one hydrogen atom from the free carbon atom of the corresponding monovalent radical. A divalent radical has two bonding sites to the rest of the molecule, which may be on the same atom or on two different atoms of the divalent radical.

[0038] "Alkylene" or "alkylidene" refers to a saturated divalent hydrocarbon group. Alkylene groups include straight chain, branched chain, cyclic or partially cyclic groups. Examples of straight chain alkylene groups are methylene groups (-CH2-), -(CH2)2-, Examples of branched alkylene groups include, but are not limited to, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, and the like. -, -CH(CH3)-CH2-, -CH(C3H7)-, -CH(C2H5)-CH2-, - C(CH3)2-CH2-, -(CH(CH3))2-, -CH(CH3)-(CH2)2-, -CH2-CH(CH3)-CH2-, -CH(C4H9)-, -C(CH3)(C3H7)-, -C(C2H5)2-, -CH(C3H7)-CH2-, -CH(C2H5)-CH(CH3)-, -CH(C2H5)-(CH2)2-, -CH2-CH(C2H5)-CH2-, -C(CH3)2-(CH2)2-, -CH2-C(CH3)2-CH2-, -CH(CH3)-(CH2)3-, -CH2-CH(CH3)-(CH2)2-, -CH(C5H 11 )-, -C(C2H5)(C3H7)-, -C(CH3)(C4H9)-, -CH(C4H9)-CH2-, -C(C2H5)2-CH2-, -C(CH3)(C3H7)-CH2-, -CH(C2H5)-CH(C2H5)-, - CH(CH3)-CH(C3H7)-, -C(CH3)2-C(CH3)2-, -CH(C3H7 )-(CH2)2-, -CH2-CH(C3H7)-CH2-, -CH(C2H5)-C(CH3 )2-, -C(CH3)2-CH(CH3)-CH2-, -CH(CH3)-C(CH3)2-CH2-, -CH(C2H5)-CH(CH3)-CH2-, -CH(CH3)-CH(C2H5)-CH2-, -CH(CH3)-CH2-CH(C2H5)-, -CH(CH3)-C(CH3 )2-CH2-, -(CH(CH3))3-, -C(CH3)2-(CH2)3-, -CH(C2 H5)-(CH2)3-, -CH2-CH(C2H5)-(CH2)2-, -CH2-CH(CH3)-CH(CH3)-CH2-, -(CH(CH3))2-(CH2)2-, -CH(CH3) These include -(CH2)2-CH(CH3)-, -(CH2)2-CH(CH3)-(CH2)2-, -CH2-CH(CH3)-(CH2)3-, and -CH(CH3)-(CH2)4-. However, the present invention is not limited to the above.

[0039] The terms "cycloalkylene group" and "cyclic alkylene group" have the same meaning and can be used interchangeably herein. Examples of cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, and cyclooctylene groups, as well as divalent polycyclic alkyl groups containing fused, spiro, or bridged rings. In some embodiments, a cycloalkylene group is a C 3~6 Cycloalkylene groups, especially C 3~4 A cycloalkylene group, in particular a cyclopropyl group.

[0040] A partially cyclic alkylene group may contain a divalent group, and the two bonding sites to the remainder of the molecule may be either one or more of the linear or branched alkyl groups, either one or more of the cycloalkyl groups, or either one or more of the cycloalkyl and linear or branched alkyl groups. Examples of partially cyclic alkylene groups include, but are not limited to, (1) cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, and cyclooctylene groups, each independently substituted with one or more linear or branched alkyl groups, and divalent polycyclic alkyl groups containing fused, spiro, or bridged rings, (2) linear or branched alkylene groups, each independently substituted with one or more cycloalkyl groups, and (3) groups obtained by combining one or more cycloalkylene groups and one or more linear or branched alkylene groups, provided that a chemically stable structure is formed. In some embodiments, a partially cyclic alkylene group may be selected from the group consisting of C 3~9 Cycloalkyl group -C1 alkylene group, preferably C 3~6 Cyclo Alkyl group-C 1~2 Alkylene group, C 3~6 cycloalkyl group -C1 alkylene group, More preferably, C 3~4 Cycloalkyl Group-C 1~2 Alkylene groups, especially C 3~4 Cycloalkyl groups are C1 alkylene groups, in particular cyclopropyl-methylene groups.

[0041] The compounds of the present invention may exist in isotopically labeled or isotopically enriched forms containing one or more atoms with atomic masses and mass numbers different from the atomic masses and mass numbers most common in nature. The isotopes may be radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine are 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 32 P, 35S, 18 F, 36 Cl and 125 Including, but not limited to, I. In one embodiment, the payload (eg, a compound of formula (i)) may be present in an isotopically labeled or isotopically enriched form, in particular a deuterated form.

[0042] As used herein, the terms "drug capable of being conjugated to an antibody" and "antibody drug conjugate" have the same meaning.

[0043] Compound of formula (i) In one aspect, the invention provides a compound or a pharma- ceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite, or prodrug thereof, said compound having the structure shown in formula (i): [ka] Where: a is 0 or 1, p1 * Carbon atom with p2 attached * Each of the carbon atoms marked with is an asymmetric center, and the asymmetric center is in the S configuration, the R configuration, or is racemized; L 1 is C 1~6 alkylene groups, unsubstituted or selected from halogen, -OH and and -NH2; M is -CH2-, -NH- or -O-; L 2 is C 1~3 is an alkylene group, R 1 and R 2 are each independently hydrogen, C 1~6 Alkyl groups, halogens and C 1~6 The alkoxy group is selected from the group consisting of aryl, ... and aryl groups.

[0044] In one embodiment, L 1 is C 1~6 Straight chain alkylene group, C1~6 Branched chain alkylene group, C 3~6 Cycloalkylene group and C 3~4 Cycloalkyl Group-C 1~2 A straight chain alkylene group is selected from the group consisting of wherein the groups are independently unsubstituted or selected from halogen, -OH and -NH2. In one embodiment, L is substituted with one substituent selected from the group consisting of aryl, ... 1 is C 1~4 Alkylene group and is unsubstituted or one selected from halogen, -OH and -NH2. In one preferred embodiment, L 1 -CH2-, -C2 H4-, [ka] wherein each of said groups is independently unsubstituted or substituted with at least one substituent selected from halogen, -OH and -NH2. In terms of form, L 1 is -CH2-, [ka] In a more preferred embodiment, L 1 is -CH2-, [ka] In particular embodiments, L 1 is -CH2-, [ka] and [ka] where "#" indicates the position of attachment to the carbonyl group. In a preferred embodiment, the halogen is selected from F, Cl and Br, in particular F.

[0045] In one embodiment, a is 1, M is -CH-, -NH-, or -O-, and L 2 In another embodiment, a is 1, M is -CH2-, and L 2 is -CH2-.

[0046] In one embodiment, p1 * The carbon atom with the symbol is preferably in the S configuration or racemized. Preferably, p2 is in the S configuration. * The carbon atom marked with is in the S configuration or racemic. It is preferably in the S configuration.

[0047] In one embodiment, R 1 and R 2 are each independently hydrogen, C 1~3 Alkyl groups, halogens and C 1~3 In one preferred embodiment, R 1 and R 2 are each independently selected from CH3-, F, Cl, Br, and CH3O-. 1 is selected from CH3- and Cl. In another embodiment, R 2 is F.

[0048] In one embodiment, L 1 is -CH2-, [ka] where "#" indicates the position of attachment to the carbonyl group. In one embodiment, a is 1 and L 1 teeth [ka] , M is O, and L2 is -C2H4-.

[0049] In one embodiment, a is 0 and R 1 is Cl, R 2 is F and L 1 is -CH2-, [ka] In one embodiment, a is 0 and R 1 is CH3- and R 2 is F , L 1 teeth, [ka] where "#" indicates the position of attachment to the carbonyl group.

[0050] In one embodiment, a is 1 and R 1 is CH3- and R 2 is F and L 1 teeth [ka] , M is O, and L 2 is -C2H4-.

[0051] In one embodiment, the compound is [ka] [ka] [ka] is selected from.

[0052] In one embodiment, the compound is [ka] [ka] is selected from.

[0053] In one preferred embodiment, the compound is [ka] [ka] is selected from.

[0054] In one preferred embodiment, the compound is [ka] is selected from.

[0055] In a more preferred embodiment, the compound is [ka] is selected from.

[0056] In a particular embodiment, the compound is [ka] is selected from.

[0057] In one aspect, the present invention provides a method for producing a method for treating a cancer cell comprising: [ka] C730 And, [ka] C731 The present invention provides a compound selected from the group consisting of:

[0058] Compounds of formula (I) In one aspect, the present invention provides a compound having the structure shown in formula (I): [ka] Where: opSu is [ka] or [ka] and R 0 is C 1~10 is an alkyl group, n is any integer from 2 to 20; k1 and k2 are independently an integer from 1 to 7; i is an integer from 1 to 100; j is an integer from 1 to 100, P1 and P2 are independently a payload having the structure shown in formula (i'), [ka] Where: a, p1 * Carbon atom with p2 * A carbon atom with L 1 , M, L 2 , R 1 and R 2 is as defined in formula (i).

[0059] In one embodiment, the payload is: [ka] [ka] [ka] is selected from.

[0060] In one embodiment, the payload comprises: [ka] [ka] is selected from.

[0061] In a preferred embodiment, the payload comprises: [ka] [ka] is selected from.

[0062] In a preferred embodiment, the payload comprises: [ka] is selected from.

[0063] In a more preferred embodiment, the payload comprises: [ka] is selected from.

[0064] In a particular embodiment, the payload comprises: [ka] is selected from.

[0065] In one embodiment, R 0 is C 1~6 In a preferred embodiment, R 0 is C1 ~3 In particular embodiments, R 0 is a methyl group.

[0066] In one embodiment, n is an integer from 2 to 5. In a particular embodiment, n is 3.

[0067] In one embodiment, k1 and k2 are independently 1 or 3 or 5. In a particular embodiment, k1 and k2 are independently 5.

[0068] In one embodiment, i is independently an integer from 1 to 20, preferably from 1 to 12, and more preferably from 2 to 8. In a particular embodiment, i is 4.

[0069] In one embodiment, j is independently an integer from 1 to 20, preferably 1 to 12, more preferably 8 to 12, in particular 8 or 12. In a particular embodiment, j is 12.

[0070] In one embodiment, the compound of formula (I) has the structure shown in formula (I-1): [ka] Where: P1, P2, R 0 , opSu, n, i and j are as defined in formula (I). do.

[0071] In one embodiment, the compound of formula (I) is [ka] BH-1 and [ka] BH-2 is selected from.

[0072] Specific embodiments of compounds of formula (I) In one embodiment, the structure of the compound of formula (I) is as shown in the table below. [Table 1-1] [Table 1-2]

[0073] Preparation of Compounds of Formula (I) In one embodiment, compounds of formula (I) can be prepared by combining a linker and a payload, or by combining a series of suitable building blocks, which are readily designed by retrosynthetic analysis and can use any method known in the art.

[0074] In one aspect, the present invention provides a compound having the structure shown in formula (1): [ka] Where: k is an integer from 1 to 7; P is a payload having the structure shown in formula (i′), where the structure shown in formula (i′) is as defined above.

[0075] In a preferred embodiment, k is 1, 3 or 5. In a particular embodiment, k is 5.

[0076] Compounds of formula (1) can be synthesized using compounds of formula (i) and other necessary building blocks in a manner similar to the synthetic methods disclosed in EP 2907824 (e.g., synthetic methods of formula (2) or (2b) in EP 2907824). Suitable building blocks include, but are not limited to, linking unit HX20113 and linking unit HX20111. [ka]

[0077] The maleimide group can then react with a mercapto group in another building block of the compound of formula (I). The resulting sulfosuccinimide is unstable under physiological conditions and can easily undergo a reverse Michael addition reaction, resulting in the decomposition of the binding site. In addition, if another sulfhydryl compound is present in the system, the thiosuccinimide can undergo thiol exchange with another sulfhydryl compound. Both of these reactions result in the loss of the payload and toxic side effects. The sulfosuccinimide is then subjected to a ring-opening reaction. The compound of formula (I) can then be obtained.

[0078] For the method of ring-opening reaction, reference may be made to International Publication No. 2015165413. Compounds containing a moiety that opens the succinimide ring can be purified by semi-preparative / preparative HPLC or other suitable separation methods to achieve high purity and accurate composition, regardless of the efficiency of the succinimide ring-opening reaction.

[0079] In the present invention, when applied to linker-payload (linker-small molecule intermediate), the ring-open succinimide structure does not allow for reverse Michael addition or thiol exchange, making the product more stable.

[0080] The portion containing the ligase acceptor or donor substrate recognition sequence In one embodiment, (Gly) of the compound of formula (I) n The moiety may be a ligase acceptor or A donor substrate recognition sequence that facilitates ligase-catalyzed enzymatic coupling of the compound of formula (I) with an antibody or antigen-binding fragment thereof. The antibody or antigen-binding fragment thereof may be modified and contains the corresponding recognition sequence for the ligase acceptor or donor substrate.

[0081] In one embodiment, the ligase is a transpeptidase. In one embodiment, the ligase is selected from naturally occurring transpeptidases, non-naturally occurring transpeptidases, variants thereof, and combinations thereof. The non-naturally occurring transpeptidase may be, but is not limited to, obtained by engineering a naturally occurring transpeptidase. In a preferred embodiment, the ligase is selected from naturally occurring Sortase enzymes, non-naturally occurring Sortase enzymes, and combinations thereof. Types of naturally occurring Sortase enzymes include Sortase A, Sortase B, Sortase C, Sortase D, Sortase L. plantarum, etc. (US Patent Publication No. 20110321183). The types of ligases correspond to ligase recognition sequences, which allow the ligase to recognize different fragments. It is used to achieve specific conjugation between the molecules or constituent fragments. In one embodiment, (Gly) of the compound of formula (I) n The portion is a ligase acceptor substrate and the antibody or antigen-binding fragment thereof may be modified to contain the corresponding recognition sequence for the ligase donor substrate.

[0082] In some embodiments, the ligase is a Sortase enzyme selected from Sortase A, Sortase B, Sortase C, Sortase D, and Sortase L. plantarum.

[0083] In a particular embodiment, the ligase is Sortase A from Staphylococcus aureus. Thus, the ligase recognition sequence may be the representative recognition sequence of the enzyme LPXTG. In another particular embodiment, the ligase donor substrate recognition sequence is LPXTGJ and the ligase acceptor substrate recognition sequence is G m and wherein X is any single natural or unnatural amino acid, and J is absent or an amino acid fragment comprising 1-10 amino acids, optionally with a tag. In one embodiment, J is absent. In another embodiment, J is an amino acid fragment comprising 1-10 amino acids, each of which is independently any natural or unnatural amino acid. In yet another embodiment, J is (Gly) m where m is an integer from 1 to 10. In certain embodiments, the ligase donor substrate recognition sequence is LPETG. In other specific embodiments, the ligase donor substrate recognition sequence is LPETGG.

[0084] In one embodiment, the ligase is Sortase B from Staphylococcus aureus and the corresponding donor substrate recognition sequence may be NPQTN, in another embodiment, the ligase is Sortase B from Bacillus anthracis and the corresponding donor substrate recognition sequence may be NPKTG.

[0085] In yet another embodiment, the ligase is Sortase A from Streptococcus pyogenes and the corresponding donor substrate recognition sequence can be LPXTGJ, where J is as defined above. In another embodiment, the ligase is Sortase subfamily 5 from Streptomyces coelicolor and the corresponding donor substrate recognition sequence can be LAXTG. In yet another embodiment, the ligase is Sortase A from Lactobacillus plantarum and the corresponding donor substrate recognition sequence may be LPQTSEQ. The ligase recognition sequence may also be any other novel transpeptidase recognition sequence that has been manually selected and optimized.

[0086] Conjugates and their preparation Additionally, compounds having a payload with a moiety comprising a ligase recognition sequence (compounds of formula (I)) can be conjugated to other molecules comprising a ligase recognition sequence and can therefore be used to prepare antibody-small molecule conjugates, such as antibody-drug conjugates. Thus, in another aspect, the present invention provides a conjugate comprising a compound of formula (I) and an antibody or antigen-binding fragment.

[0087] In another aspect, the present invention provides a conjugate having the structure shown in formula (II): [ka] Where: A is an antibody or an antigen-binding fragment thereof, z is an integer from 1 to 20; P1, P2, R 0 , opSu, n, k1, k2, i and j are defined in formula (I). As stated above.

[0088] In a preferred embodiment, the antibody or antigen-binding fragment thereof is modified to modify (Gly) in the compound of formula (I). n Bind to the part.

[0089] In a preferred embodiment, z is 1 to 4. In a particular embodiment, z is 2.

[0090] Antibody or antigen-binding fragment thereof In one embodiment, the antibodies are anti-CD19 antibodies, anti-CD20 antibodies, anti-CD22 antibodies, anti-CD25 antibodies, anti-CD30 / TNFRSF8 antibodies, anti-CD33 antibodies, anti-CD37 antibodies, anti-CD4 4v6 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD71 antibody, anti-CD74 antibody, anti-CD79b antibody, anti-CD117 / KITk antibody, anti-CD123 antibody, anti-CD138 antibody, anti- CD142 antibody, anti-CD174 antibody, anti-CD227 / MUC1 antibody, anti-CD352 antibody, anti-CLDN18.2 antibody, anti-DLL3 antibody, anti-ErbB2 / HER2 antibody, anti-CN33 antibody, anti-GPNMB antibody, anti-ENPP3 antibody, anti-Nectin-4 antibody, anti-EGFRvIII antibody, anti-SLC44A4 / AGS-5 antibody, anti-CEACAM5 antibody, anti-PSMA antibody, Anti-TIM1 antibody, anti-LY6E antibody, anti-LIV1 antibody, anti-Nectin4 antibody, anti-SLITRK6 antibody, anti-HGFR / cMet antibody, anti-SLAMF7 / CS1 antibody, anti-EGFR antibody, anti-BCMA antibody, anti-AXL antibody, anti-NaPi antibody 2B antibody, anti-GCC antibody, anti-STEAP1 antibody, anti-MUC16 antibody, anti-Mesothelin antibody, anti-ETBR antibody, anti-EphA2 antibody, anti-5T4 antibody, anti-FOLR1 antibody, anti-LAMP1 antibody, anti-Cadherin6 antibody, anti- The antibody is an FGFR2 antibody, an anti-FGFR3 antibody, an anti-CA6 antibody, an anti-CanAg antibody, an anti-integrin αV antibody, an anti-TDGF1 antibody, an anti-EphrinA4 antibody, an anti-TROP2 antibody, an anti-PTK7 antibody, an anti-NOTCH3 antibody, an anti-C4.4A antibody, an anti-FLT3 antibody, an anti-B7H3 / 4 antibody, an anti-TissueFactor antibody or an anti-ROR1 / 2 antibody, and preferably an anti-HER2 antibody, an anti-FGFR3 antibody, an anti-Trop2 antibody, an anti-HER3 antibody or an anti-FRα antibody.

[0091] In a preferred embodiment, the antibody is an anti-HER2 antibody. In one embodiment, the antibody is an anti-human HER2 antibody. Examples of anti-human HER2 antibodies include, but are not limited to, Pertuzumab and Trastuzumab. Pertuzumab binds to the second extracellular domain (ECD2) of HER2 and is approved for the treatment of HER2-positive breast cancer. Trastuzumab binds to the fourth extracellular domain (ECD4) of HER2 and is approved for the treatment of HER2-positive breast and gastric cancer.

[0092] In one embodiment, the antibody is an anti-HER2 antibody or an antigen-binding fragment thereof, and comprises a light chain variable domain (V L ) and the heavy chain variable domain (V H ), of which V L LCDR1, LCD LCDR1 comprises the amino acid sequence of SEQ ID NO: 1, LCDR2 comprises the amino acid sequence of SEQ ID NO: 2, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 3, wherein H , HCDR1, HCDR HCDR1 comprises the amino acid sequence of SEQ ID NO:4, HCDR2 comprises the amino acid sequence of SEQ ID NO:5, and HCDR3 comprises the amino acid sequence of SEQ ID NO:6. In one embodiment, the CDRs are defined by KABAT. In one embodiment, the antibody is an anti-HER2 antibody or antigen-binding fragment thereof, and comprises a light chain variable domain (V L ) and the heavy chain variable domain (V H ), of which V L is the SEQ ID having an amino acid sequence that exhibits at least 85%, at least 90%, or at least 95% sequence identity to NO:7, and H For SEQ ID NO: 8, In a preferred embodiment, the anti-HER2 antibody or antigen-binding fragment thereof has an amino acid sequence that exhibits at least 85%, at least 90%, or at least 95% sequence identity with the light chain variable domain (V L ) and the heavy chain variable domain (V H ), of which V L is SEQ ID NO: 7, and VH is the amino acid sequence of SEQ ID NO: 8 In a particular embodiment, the anti-HER2 antibody comprises a light chain and a heavy chain, wherein the light chain has an amino acid sequence that exhibits at least 85%, at least 90%, or at least 95% sequence identity to the amino acid sequence of amino acids 1 to 214 of SEQ ID NO: 9, and the heavy chain has an amino acid sequence that exhibits at least 85%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 10. In a preferred embodiment, the anti-human HER2 antibody is one or more selected from engineered anti-HER2 antibodies based on trastuzumab. In one embodiment, the antibody is a modified trastuzumab, preferably Ab0001-LCCT. L -HC (light chain SEQ ID NO:9 , heavy chain SEQ ID NO:10). Antibody Ab0001-LCCT L -H The sequence of C is based on the amino acid sequence of trastuzumab, with GALPETGG introduced at the C-terminus of the light chain, in which LPETGG is a recognition sequence for the ligase donor substrate and GA is a spacer sequence.

[0093] In a preferred embodiment, the anti-human HER2 antibody is a recombinant antibody and is selected from a monoclonal antibody, a chimeric antibody, a humanized antibody, an antibody fragment, and an antibody mimetic. In one embodiment, the antibody mimetic is selected from an scFv, a minibody, a bibody, and a nanobody. For conjugates with the compound of formula (I), the antibody or antigen-binding fragment thereof of the present invention is selected from (Gly) in the compound of formula (I). n The modified moiety may be included for conjugation to the moiety. The position at which such a modifying moiety is introduced is not limited, and for example, the position at which the antibody or antigen-binding fragment thereof is introduced may be, but is not limited to, the C-terminus or N-terminus of the heavy or light chain of the antibody.

[0094] In a preferred embodiment, (Gly) in the compound of formula (I) n Parts and Conjugations The modifying moiety for this purpose can be introduced into the antibody at a position other than the terminus of the heavy or light chain, for example, by chemical modification methods.

[0095] In one embodiment, the antibody or antigen-binding fragment thereof may include a terminal modification. Terminal modification refers to a modification at the C-terminus or N-terminus of the heavy or light chain of the antibody, including, for example, a ligase recognition sequence. In another embodiment, the terminal modification includes a spacer Sp comprising 2 to 100 amino acids. It may further comprise an antibody, Sp and a ligase recognition sequence linked in that order. In a preferred embodiment, Sp is a spacer sequence comprising 2 to 20 amino acids. In a particular embodiment, Sp is a spacer sequence selected from GA, GGGGS, GGGGSGGGGS and GGGSGGGGSGGGGGS, in particular GA.

[0096] In a preferred embodiment, the light chain of the antibody or antigen-binding fragment thereof is selected from the group consisting of wild type (LC), C-terminal modified light chain (LCCT) modified by directly introducing the ligase recognition sequence LPETGG, and C-terminal modified light chain (LCCT) modified by introducing a short peptide spacer and the ligase donor substrate recognition sequence LPXTG. L ) Antibody or its antigen binding The heavy chains of the fusion fragments were wild type (HC), C-terminal modified light chains (HCCT) modified by directly introducing the ligase recognition sequence LPXTG, and C-terminal modified light chains (HCCT) modified by introducing a short peptide spacer and the ligase donor substrate recognition sequence LPXTG. L ) X may be any natural or unnatural single amino acid. When z in the compound of formula (II) is 1 or 2, the heavy and light chains can combine to form eight preferred antibody molecules.

[0097] In one embodiment, the compound of formula (II) is [ka] and [ka] is selected from. Specific embodiments of the conjugates In one embodiment, the payload is a cytotoxin or a fragment thereof. In one embodiment, the antibody-drug conjugate is as shown in the table below.

[0098] ADC nomenclature: The number in parentheses is the number of payload (drug) molecules intended to be attached to the antibody.

[0099] [Table 2]

[0100] Preparation of conjugates The conjugate of the present invention (i.e., the compound of formula (II)) can be prepared by any method known in the art. In some embodiments, the conjugate is prepared by ligase-catalyzed site-specific conjugation of an antibody or antigen-binding fragment with a compound of formula (I), where the antibody or antigen-binding fragment is modified with a ligase recognition sequence.

[0101] The antibody or antigen-binding fragment thereof and the compound of formula (I) are linked to each other via a substrate ligase-specific recognition sequence. The recognition sequence depends on the specific ligase used. In one embodiment, the antibody or antigen-binding fragment thereof is an antibody having a terminal modification based on the recognition sequence introduced at the C-terminus of the light chain and / or heavy chain, and the antibody or antigen-binding fragment thereof is conjugated to the compound of formula (I) under suitable catalytic reaction conditions with a wild-type or optimized engineered ligase or any combination thereof as a catalyst.

[0102] In a specific embodiment, the ligase is Sortase A and the conjugation reaction may be represented in the following solution: [ka] The triangle represents a portion of an antibody, the pentagon represents a portion of a compound of formula (I), and G n (G ly) n represents the moiety. n, X, and J are each as defined above. The corresponding recognition sequence of the acceptor substrate G n When conjugated with The peptide bond upstream of the glycine in is cleaved by Sortase A, and the resulting intermediate is G n The resulting amino acid is then bonded to the free N-terminus of the corresponding amino acid to form a new peptide bond. The amino acid sequence is LPXTG n The array G n and LPXTGJ are as defined above.

[0103] Thus, in one embodiment, G of the compound of formula (I) n The portion is a ligase acceptor The antibody is modified to include a ligase donor substrate recognition sequence, thereby forming a ligase donor substrate recognition sequence of the compound of formula (I). n Binding to the part, Preferably, (a) the ligase is a sortase enzyme selected from Sortase A, Sortase B, Sortase C, Sortase D and Sortase L. plantarum, preferably Sortase A from Staphylococcus aureus; and / or (b) the ligase donor substrate recognition sequence is LPXTGJ, where J is absent or G m wherein G is glycine, m is an integer from 1 to 10, and X is any natural or non-natural and / or LPXTG is G n Binds to LPXTG n Generate.

[0104] The compounds of formula (I) of the present invention have the correct structure, correct composition and high purity, so that when they are subjected to a conjugation reaction with an antibody, very little or no impurities are introduced. When such intermediates are used for site-specific conjugation with a modified antibody containing a ligase recognition sequence catalyzed by a ligase, a homogenous ADC with highly controllable quality is obtained.

[0105] Metabolism of the conjugate in physiological environments When the linker is partially or entirely degraded in the tumor cell, the payload is released. Because the linker is degraded at the site where it is attached to the antitumor compound, the antitumor compound is released in its native conformation to exert its native antitumor activity.

[0106] In one embodiment, the GGFG (Gly-Gly-Phe-Gly) moiety contained in the compound of formula (I) may be degraded by lysosomal enzymes (eg, cathepsin B and / or cathepsin L).

[0107] In one embodiment, the compound of formula (I) comprises a self-immolative spacer. In one embodiment, the self-immolative spacer is an acetal or heteroacetal. In one embodiment, the -GGFG-NH-CH2-O- moiety in the compound of formula (I) is a self-immolative spacer that is an acetal or heteroacetal. These represent combinations of ligand-binding proteins and ligand-binding proteins that degrade in the cell and release target molecules (eg, anti-tumor compounds).

[0108] Pharmaceutical Compositions and Formulations Another object of the present invention is to provide a pharmaceutical composition comprising the conjugate of the present invention and at least one pharma- ceutically acceptable carrier.

[0109] The pharmaceutical composition of the present invention can be administered in any manner as long as it can achieve the effect of preventing, alleviating, preventing or treating symptoms in humans or animals. For example, it can be prepared into various suitable dosage forms, particularly injections such as lyophilized powder for injection and sterile powder for injection, depending on the administration route.

[0110] The term "pharmacologically acceptable" means, within the scope of sound medical judgment, that is in contact with the tissues of a patient without causing undue toxicity, irritation, allergic response or the like, and is effective for its intended use with a reasonable benefit / risk ratio.

[0111] The term "pharmaceutical acceptable carrier" refers to such a carrier material that is pharmaceutical acceptable and does not impair the biological activity and properties of the conjugate. Aqueous carriers include, but are not limited to, buffered saline and the like. Pharmaceutically acceptable carriers further include carrier materials that make the composition closer to physiological conditions, such as pH adjusting agents, buffering agents, toxicity adjusting agents, and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, and the like.

[0112] In one embodiment, the drug / antibody ratio (DAR) of the pharmaceutical composition of the invention is an integer or non-integer of about 1 to about 20, for example, an integer or non-integer of about 1 to about 10, about 1 to about 8, about 1 to about 6, about 1 to about 4, about 2 to about 5, about 2 to about 4, or about 3 to about 4. In a particular embodiment, the conjugate of the invention has a DAR of about 4. In a particular embodiment, the conjugate of the invention has a DAR of about 3.3 to about 3.75, particularly about 3.4 to about 3.65.

[0113] Treatment Methods and Uses The conjugates of the present invention can be used to treat tumors and / or autoimmune diseases. Tumors susceptible to treatment with the conjugates include tumors characterized by specific tumor-associated antigens or cell surface acceptors, whose tumor cells are recognized by the target molecule (antibody) of the conjugate and further killed by the payload / cytotoxin of the conjugate.

[0114] Thus, in another aspect, the present invention further provides the use of a conjugate of the present invention or a pharmaceutical composition of the present invention in the manufacture of a medicament for treating a disease, condition or pathology selected from a tumor or an autoimmune disease.

[0115] In another aspect, the present invention provides a method for the treatment of a tumor or an autoimmune disease using a conjugate of the present invention. The present invention also provides a pharmaceutical composition according to the present invention.

[0116] In a further aspect, the present invention provides a method for treating a tumor or an autoimmune disease comprising administering to an individual in need thereof an effective amount of a conjugate of the present invention or a pharmaceutical composition of the present invention.

[0117] In a preferred embodiment, the conjugate formed by binding an anti-HER2 antibody to a small molecule cytotoxin according to the present invention can specifically bind to HER2 on the surface of tumor cells and selectively kill tumor cells expressing HER2. In another preferred embodiment, the anti-HER2 antibody is an anti-human HER2 antibody. In another preferred embodiment, the present invention provides a use of the conjugate of the present invention or the pharmaceutical composition of the present invention in the manufacture of a medicament for treating a disease, condition or symptom selected from HER2-positive tumors. In a more preferred embodiment, the disease, condition or symptom is selected from breast cancer, gastric cancer, lung cancer, ovarian cancer, urothelial cancer, etc.

[0118] The dose of the conjugate administered to a subject can be adjusted to a large extent. The dose will vary depending on the particular route of administration and the needs of the subject, and can be determined by a medical professional.

[0119] As defined above, embodiments of the present invention may be described as follows [1] to

[20] : [1] A compound of formula (I) [ka] Where: opSu is [ka] or [ka] and R 0 is C 1~10 is an alkyl group, n is any integer from 2 to 20; k1 and k2 are independently an integer from 1 to 7; i is an integer from 1 to 100; j is an integer from 1 to 100, P1 and P2 are independently a payload having the structure shown in formula (i'), [ka] Where: a is 0 or 1, p1 * Carbon atom with p2 attached * each carbon atom marked with is an asymmetric center, and said asymmetric center is in the S configuration, the R configuration or is racemized; L 1 is C 1~6 alkylene groups, unsubstituted or selected from halogen, -OH and and -NH2; M is -CH2-, -NH- or -O-; L 2 is C 1~3 is an alkylene group, R 1 and R 2 are each independently hydrogen, C 1~6 Alkyl groups, halogens and C 1~6 The compound selected from the group consisting of alkoxy groups.

[0120] [2] It has a structure shown in formula (I-1), [ka] Where: P1, P2, R 0 , opSu, n, i and j are as defined in claim 1. The compound according to claim [1].

[0121] [3] In formula (i'), L 1 is C 1~6 Straight chain alkylene group, C 1~6 Branched chain alkylene group, C 3~6 Cycloalkyl C groups and 3~4 Cycloalkyl Group-C 1~2 straight chain alkylene groups, each of which is independently unsubstituted or has one substituent selected from halogen, -OH and -NH2. is substituted by a substituent, Preferably, L 1 is C 1~4 Straight chain alkylene group, C 1~4 Branched chain alkylene group, C 3~4 Cycloalkyl a cyclopropyl group, a cyclopropyl group, and a cyclopropyl-methylene group, each of said groups being independently unsubstituted or substituted with one substituent selected from halogen, -OH and -NH2; It has been Preferably, L 1 -CH2-, -C2H4-, [ka] each of said groups is independently unsubstituted or substituted with at least one substituent selected from halogen, -OH and -NH; More preferably, L 1 is -CH2-, [ka] where "#" indicates the position of attachment to the carbonyl group; More preferably, L 1 is -CH2-, [ka] where "#" indicates the position of attachment to the carbonyl group; In particular, L 1 is -CH2-, [ka] and [ka] where "#" indicates the position of attachment to the carbonyl group; and / or The compound according to claim [1] or [2], wherein the halogen is selected from F, Cl and Br.

[0122] [4] In formula (i'), M is -CH2-, -NH- or -O-; L 2 is -C2H4-, or M is -CH2-, L 2 is -CH2-, any one of claims [1] to [3] The compound according to claim 1,

[0123] [5] In formula (i'), p1 * The carbon atom marked with is in the S configuration or racemized, preferably in the S configuration. Yes and / or p2 * The carbon atom marked with is in the S configuration or racemized, preferably in the S configuration. The compound according to any one of claims [1] to [4].

[0124] [6] In formula (i'), R 1 and R 2 are each independently hydrogen, C 1~3 Alkyl groups, halogens and C 1~3 alkoxy groups, Preferably, R 1 and R 2are each independently selected from CH3-, F, Cl, Br, and CH3O-; More preferably, R1 is selected from CH3- and Cl; and / or R 2 is F, More preferably, a is 0 and R 1 is Cl, R 2 is F and L 1 is -CH2-, [ka] Alternatively, a is 0, R 1 is CH3- and R 2 is F and L 1 teeth, [ka] where "#" indicates the position of attachment to the carbonyl group; or a is 1 and R 1 is CH3- and R 2 is F and L 1 teeth [ka] , M is O, and L 2 is -C2H4-, any one of claims [1] to [5] The compound according to claim 1,

[0125] [7] The payload is [ka] [ka] is selected from Preferably, [ka] is selected from More preferably, [ka] is selected from especially, [ka] The compound according to any one of claims [1] to [6], selected from:

[0126] [8] R 0 is C 1~6 is an alkyl group, preferably C 1~3 an alkyl group, in particular a methyl group, and / or n is an integer from 2 to 5, in particular 3, and / or k1 and k2 are independently 1 or 3 or 5, in particular 5; i is independently an integer from 1 to 20, preferably from 1 to 12, more preferably from 2 to 8, in particular 4; and / or The compound according to any one of claims [1] to [7], wherein j is independently an integer of 1 to 20, preferably 1 to 12, more preferably 8 to 12, particularly 8 or 12, and especially 12.

[0127] [9] [ka] [ka] The compound according to any one of claims [1] to [8], which is selected from the following:

[0128]

[10] Having the structure shown in formula (II), [ka] Where: A is an antibody or an antigen-binding fragment thereof, said antibody or antigen-binding fragment thereof being preferably modified to modify (Gly) in the compound of formula (I). n Binding to the part, z is an integer from 1 to 20, preferably from 1 to 4, and particularly preferably 2; P1, P2, R 0 , opSu, n, k1, k2, i and j are as defined in claims [1] to [8]. A conjugate as defined in any one of the claims.

[0129]

[11] [ka] The conjugate of claim

[10] , which is selected from the group consisting of

[0130]

[12] The conjugate of claim

[10] or

[11] , wherein the antibody is an anti-human HER2 antibody, preferably trastuzumab.

[0131]

[13] A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the conjugate according to any one of claims

[10] to

[12] and at least one pharma- ceutically acceptable carrier.

[0132]

[14] The pharmaceutical composition of claim 13, wherein the drug / antibody ratio (DAR) of the conjugate is an integer or non-integer between 1 and 8, in particular an integer or non-integer between 3 and 4.

[0133]

[15] Use of the conjugate according to any one of claims

[10] to

[12] or the pharmaceutical composition according to claim

[13] or

[14] in the manufacture of a medicament for treating a disease, wherein the disease is a tumor or an autoimmune disease, preferably a tumor comprising HER2-positive tumor cells.

[0134]

[16] the tumor comprising HER2-positive tumor cells further comprises HER2 low expressing tumor cells; The use of claim

[15] , wherein the HER2 expression level of the HER2-low expressing tumor cells is lower than that of the HER2-positive tumor cells.

[0135]

[17] Having the structure shown in formula (i), [ka] Where: a, p1 * Carbon atom with p2 * A carbon atom with L 1 , M, L 2 , R 1 and R 2 is as defined in any one of claims [1] to [7], or a pharma- ceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotopomer, metabolite, or prodrug thereof.

[0136]

[18] [ka] [ka] is selected from Preferably, [ka] is selected from More preferably, [ka] is selected from especially, [ka] The compound according to claim

[17] , which is selected from the group consisting of

[0137]

[19] A compound of formula (1), [ka] Where: k is an integer from 1 to 7, preferably 1 or 3 or 5, in particular 5; A compound, wherein P is a payload having a structure shown in formula (i'), and the structure shown in formula (i') is as defined in any one of claims [1] to [7].

[0138]

[20] [ka] The conjugate of claim

[19] , which is selected from the group consisting of

[0139] The novel small molecule topoisomerase I inhibitors of the present invention, when used alone or as components of ADCs, can exhibit improved activity, stability and physicochemical properties over the prior art.

[0140] The antibody-drug conjugate of the present invention can achieve high efficacy and bystander killing effect by using a specially designed linker-payload. And because it has a low DAR, it can reduce side effects and improve the therapeutic index, which is very important for bystander killing. The antibody-drug conjugate of the present invention has a more stable structure such as an open-ring succinimide structure.

[0141] The present invention utilizes a linker with a unique structure and catalyzes the conjugation of a target molecule (antibody) with a payload using a ligase. The conjugate of the present invention has high homogeneity and high activity. In addition, the toxicity of the linker unit-payload intermediate is much lower than that of the free payload, so it is less hazardous during the drug manufacturing process and is convenient for industrialized production.

[0142] The conjugates of the present invention achieve at least one of the following technical advantages. (1) It has high inhibitory activity against target cells and also has a high bystander killing effect.

[0143] (2) Excellent physicochemical properties (e.g., solubility, physical and / or chemical stability).

[0144] (3) It has excellent pharmacokinetic properties (e.g., high stability in plasma, appropriate half-life and duration of action).

[0145] (4) Safety (low toxicity and / or few side effects on non-target normal cells or tissues, widespread use) It has excellent properties such as a low therapeutic range.

[0146] (5) The highly modular design allows for easy combination of different drugs. EXAMPLES

[0147] Preparation Examples In order to more clearly explain the purpose and technical means of the present invention, the present invention will be further described below with reference to specific examples. It should be understood that these examples are only for illustrating the present invention and do not limit the scope of the present invention. Any specific experimental methods not mentioned in the following examples are all carried out according to conventional experimental methods. Equipment, materials and reagents

[0148] Unless otherwise stated, all the instruments and reagents used in the examples are commercially available. The reagents can be used as they are without purification.

[0149] MS: Thermo Fisher Q Exactive Plus, Water2795-Quattro micro triple quadrupole mass spectrometer HPLC: Waters 2695, Agilent 1100, Agilent 1200 Semi-preparative HPLC: Lisure HP plus 50D Flow cytometer: CytoFLEX S HIC-HPLC: Butyl-HIC, mobile phase A: 25mM PB, 2M (NH4 )2SO4, pH 7.0, mobile phase B: 25 mM PB, pH 7.0, flow rate: 0.8 mL / min; collection time: 25 min, sample injection amount: 20 μg; column temperature: 25 °C; detection wavelength: 210 nm; sample chamber temperature: 8 °C. SEC-HPLC: Chromatography column: TSK-gel G3000 SWXL, TOSOH 7.8 mm ID x 300 mm, 5 μm, mobile phase: 0.2 M KH2P O4, 0.25M KCl, pH 6.2, flow rate: 0.5mL / min; collection time: 30 min, sample injection volume: 50 μl, column temperature: 25 °C; detection wavelength: 210 nm; sample pan temperature: 8 °C. CHO cells were obtained from Thermo Fisher Scientific, pcDNA3.3 was obtained from Life Technology, HEK293F was obtained from Prejin, PEIMAX transfection reagent was obtained from Polyscience, MabSelect Sure ProA was obtained from GE, and Capto S ImpAct was obtained from GE, Rink-amide-MBHA-resin and dichloro resin were obtained from Nankai synthesis, HCC1954 was obtained from ATCC CAT# CRL-2338, SK-BR-3 was obtained from ATCC CAT# HTB-30, BT-474 was obtained from ATCC CAT# HTB-20, NCI-N87 (ATCC Cat # CRL-5822), MCF7 was obtained from ATCC CAT# HTB-22, MDA-MB-231 was obtained from ATCC CAT# HTB-26, MDA-MB-468 was obtained from ATCC CAT# HTB-132, CFPAC-1 was obtained from ATCC CAT# CRL-1918, NCI-H2110 was obtained from ATCC CAT# CRL-5924, JIMT-1 was obtained from Wuxi Apptech, Capan-1 was obtained from ATCC CAT# CRL-1573, the antibody trastuzumab was produced based on a known sequence and was transformed in E. coli with Staphylococcus aureus. We have produced an optimized recombinase, Sortase A, derived from Phylocococcus aureus.

[0150] In some cases, the order of carrying out the above reaction schemes can be varied to facilitate the reaction or to avoid unwanted reaction products. In order that this invention may be more fully understood, the following examples are provided. These examples are merely illustrative and should not be construed as limiting the invention in any manner. EXAMPLES

[0151] Preparation of payload small molecules Intermediate 11 [ka] Step A: N-(2-bromo-5-fluorophenyl)acetamide: To a stirred solution of acetic anhydride (214 g, 2.10 mol) and acetic acid (500 mL) was added concentrated H2SO4 (3 mL) followed by the addition of 2-bromo-5-fluoroaniline (100 g, 526.27 mmol) in small portions at room temperature. The mixture was stirred for 3 h and then poured into 2000 mL of ice water. A precipitate formed, was collected by filtration, and dried under vacuum at room temperature to give N-(2-bromo-5-fluorophenyl)acetamide (105 g) as a yellow solid. 1 H NMR(400MHz,DMSO-d6)δ7.68(dd,J=8.9,6.0Hz, 1H),7.61(ddd,J=10.7,5.3,3.1Hz,1H),7.02(ddd,J=8.9,8.0,3.1Hz,1H),2.11(s,3H).LCMSm / z232.0[M+H] + .

[0152] Step B: N-(5-fluoro-2-(1-hydroxycyclobutyl)phenyl)acetamide:-78 o C while stirring for 1 h. To a solution of (phenyl)acetamide (105 g, 452.48 mmol) and THF (1000 mL) was added n-BuLi (594 mL, 1.6 M in n-hexane, 950.22 mmol) dropwise. After completion, the mixture was stirred with N2 for 0.5 h. Then, -78 o C, a solution of cyclobutanone (38.06 g, 542.98 mmol) and THF (50 mL) was added dropwise within 0.5 h, and the mixture was heated to -78 o C and stirred at room temperature for 6 h. o C, the mixture was poured into 500 mL of saturated aqueous NH4Cl solution, extracted with ethyl acetate (500 mL x 3), and then washed with brine. (250mLx2), dried over Na2SO4 and concentrated. The mixture was triturated with (PE / EA=1:1, 100mL) for 10 min, filtered to collect the filter cake and dried in vacuum to give N-(5-fluoro-2-(1-hydroxycyclobutyl)phenyl)acetamide (24g) as a yellow solid. LCMS m / z 206.1 (M-18+H), 24 6.1(M+Na).

[0153] Step C: N-(3-fluoro-8-oxo-5,6,7,8-tetralin-1-yl)acetamide: Add N-(5-fluoro-2-(1-hydroxycyclobutyl)phenyl)acetamide (24 g, 107.50 mmol) and CHCl( Silver nitrate (AgNO3) (5.48 g) was added to a mixture of 170 mL of ethyl acetate and 170 mL of water. , 32.25 mmol) and potassium persulfate (K2S2O8) (58.12 g, 215.0 1 mmol) was added and the mixture was stirred for 30 o The mixture was stirred at C for 6 h. The mixture was filtered through diatomaceous earth and Wash with H2Cl2 (100 mL), and concentrate the filtrate to FCC (EA / PE = 0-40%). The resultant was purified by HPLC to give N-(3-fluoro-8-(oxo)-5,6,7,8-tetralin-1-yl))acetamide (14 g) W as a pale yellow solid. LCMS m / z 222.1 [M+H] + .

[0154] Step D: N-(3-fluoro-7-(hydroxyimino)-8-oxo-5,6,7,8-tetralin-1-yl)acetamide: 0 o C, while stirring, N-(3- To a mixture of fluoro-8-oxo-5,6,7,8-tetralin-1-yl)acetamide (14 g, 63.28 mmol) and THF (500 mL) was added 1-butyl nitrite (8.48 g, 63.28 mmol), followed by t-BuOK (8.52 g, 75.94 mmol). oC for 2 h. After completion, the mixture was diluted with HCl (2N ) to adjust pH=3. The mixture was extracted with ethyl acetate (200mLx3), washed with brine (100mLx2), dried over Na2SO4, and concentrated under reduced pressure. The crude mixture was triturated with methyl tert-butyl ether (200mL) for 10 min, filtered to collect the filter cake, and dried in vacuum to give N-(3-fluoro-7-(hydroxyimino)-8-oxo-5,6,7,8-tetralin-1-yl)acetamide (12g) as a yellow solid. LCMS m / z 251.1 [M+H] + .

[0155] Step E: N,N′-(3-fluoro-8-oxo-5,6,7,8-tetralin-1,7-diyl)diacetamide: To a solution of N-(3-fluoro-7-(hydroxyimino)-8-oxo-5,6,7,8-tetralin-1-yl)acetamide (12 g, 47.96 mmol), acetic anhydride (90 mL) and THF (90 mL) was added 10% Pd / C (1 g) and the mixture was stirred for 25 min. o C under H2 atmosphere for 16 h. o Cool to C Then, Et3N (20 mL) was added dropwise and the mixture was cooled to 0 o C for 1 h. Filtered through diatomaceous earth, the filtrate was poured into ice water (500 mL). Extracted with ethyl acetate (500 mLx3), washed with brine (250 mLx2), dried over Na2SO4 and concentrated. The residue was triturated with methyl tert-butyl ether (120 mL) for 10 min, filtered, collected the filter cake and dried in vacuum to give N,N′-(3-fluoro-8-oxo-5,6,7,8-tetralin-1,7-diyl)diacetamide (7.9 g) as a yellow solid. LCMS m / z 279.1 [M+H] + .

[0156] Step F: N,N′-(3-fluoro-8-oxo-5,6,7,8-tetralin-1,7-diyl)diacetamide: To a solution of N,N′-(3-fluoro-8-oxo-5,6,7,8-tetralin-1,7-diyl)diacetamide (7.9 g, 28.39 mmol) and MeOH (150 mL) was added aqueous HCl (2 N, 150 mL) and the mixture was stirred for 50 min. o C for 7 h. o After cooling to C, a saturated aqueous solution of NaHCO3 was added dropwise. The pH was adjusted to 8. It was extracted with ethyl acetate (200 mL x 3), washed with brine (200 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to give N,N'-(3-fluoro-8-oxo-5,6,7,8-tetralin-1,7-diyl)diacetamide (6.0 g) as a yellow solid. 1 H NMR(400MHz,Chloroform-d)δ6.57(s ,3H),6.18(td,J=11.1,2.4Hz,2H),4.52(dt,J=13.3,5.0Hz,1H),3.13(ddd,J=17.5,13.0,4.6H z,1H),3.00-2.81(m,1H),2.69(dtd,J=9.4,4.6,2.5Hz,1H),2.09(s,3H),1.79(qd,J=13.0,4.3Hz,1H).LCMSm / z237.1[M+H] + .

[0157] Step G: N-(8-amino-5-chloro-6-fluoro-1-oxo-1,2,3,4-tetralin-2-yl)acetamide: 0 o C, N,N′-(3-fluoro- To a solution of 8-oxo-5,6,7,8-tetralin-1,7-diyl)diacetamide (4.0 g, 16.93 mmol) and DMF (80 mL) was added NCS (2.26 g, 16.93 mmol) in small portions and the mixture was stirred at room temperature for 16 h. The mixture was poured into 200 mL of ice water. A precipitate formed, was collected by filtration, and dried in vacuum at room temperature to give N-(8-amino-5-chloro-6-fluoro-1-oxo-1,2,3,4-tetralin-2-yl)acetamide (4.0 g) as a yellow solid. 1 H NMR (400MH z,DMSO-d6)δ8.11(d,J=8.0Hz,1H),7.71(s,2H) ,6.62(d,J=11.9Hz,1H),4.53(ddd,J=13.0,8.0,4.7Hz,1H),3.18-3.04(m,1H),2.91(d dd,J=17.5,12.4,4.8Hz,1H),2.21-2.08(m,1H),1.99-1.83(m,4H).LCMSm / z271.0[M+H] + .

[0158] Step H: N-((9S)-4-chloro-9-ethyl-5-fluoro-9-hydroxyl-10,13-di(oxo)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)acetamide: N-(8-amino-5-chloro-6-fluoro-1-oxo-1,2,3,4-tetralin-2-yl)acetamide (4.0 g) To a mixture of (S)-4-ethyl-4-hydroxyl-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (4.28 g, 16.25 mmol), pyridinium p-toluenesulfonate (1.11 g, 4.43 mmol) and orthocresol (10 mL) was added, and the mixture was heated to reflux with N2 and held for 24 h. The solvent was removed under reduced pressure, and the mixture was purified by FCC chromatography. Purification by HPLC using THF / CHCl=0-60% gave brown solid N-((9S)-4-chloro-9-ethyl-5-fluoro-9-hydroxyl-10,13-di(oxo)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)acetamide (4.1 g). LCMS m / z 498.1 [M+H] + .

[0159] Step I: (9S)-1-amino-4-chloro-9-ethyl-5-fluoro-9-hydroxyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-10,13-dione: 70 o C, N-((9S)-4-chloro-9-ethyl-5-fluoro-9- A mixture of hydroxyl-10,13-di(oxo)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)acetamide (2.0 g, 4.02 mmol) in 20 mL of concentrated aqueous HCl was stirred under N2 for 36 h. The mixture was concentrated under reduced pressure to give a brown solid. The crude product (9S)-1-amino-4-chloro-9-ethyl-5-fluoro-9-hydroxyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-10,13-dione hydrochloride (2g) was obtained as a crude product. LCMS (ESI) m / z 456.1 [M+H] + .

[0160] Intermediate 12 [ka] Intermediate 12: (9S)-1-amino-4-bromo-9-ethyl-5-fluoro-9-hydroxyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-10,13-dione hydrobromide was synthesized from 2-bromo-5-fluoroaniline in a manner similar to that of Intermediate 11. LCMS (ESI) m / z 500.0 [M+H] + .

[0161] Intermediate 13 [ka] Intermediate 13: (9S)-1-amino-9-ethyl-5-fluoro-9-hydroxyl-4-methoxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-10,13-dione hydrochloride was synthesized from 2-bromo-5-fluoro-4-methoxyaniline in a manner similar to that of Intermediate 11. LCMS (ESI) m / z 452.1 [M+H] + .

[0162] Methods C730 and C731 [ka] C730 and C731 were prepared as TFA salt forms from (9S)-1-amino-4-chloro-9-ethyl-5-fluoro-9-hydroxyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-10,13-dione hydrochloride (Intermediate 11) by preparative HPLC.

[0163] Table I [Table 3]

[0164] C518 Method [ka] Step J: N-((1S,9S)-4-chloro-9-ethyl-5-fluoro-9-hydroxyl-10,13-di(oxo)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)-2-hydroxyacetamide: crude product (9S)-1-amino-4-chloro-9-ethyl-5-fluoro To a solution of 9-hydroxyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-10,13-dione hydrochloride (50 mg, 0.10 mmol) and 2 mL of DMF, 2-hydroxyacetic acid (11.6 mg, 0.15 mmol) and HATU (57.9 mg, 0.15 mmol) were added, followed by 0.1 mL of DMF. o C, EtN (20.5 mg, 0.20 mmol) was added dropwise and the mixture was cooled to 0 o C to room temperature and stir for 2 h The mixture was poured into 10 mL of ice water, extracted with ethyl acetate (20 mLx3), washed with brine (20 mLx2), dried over Na2SO4 and concentrated. The residue was purified by preparative HPLC to give N-((1S,9S)-4-chloro-9-ethyl-5-fluoro-9-hydroxyl-10,13-di(oxo)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)-2-hydroxyacetone as a yellow solid. The resulting mixture was concentrated to give 1,2-dihydro-1,3-di(oxo)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)-2-hydroxyacetamide (6 mg), and yellow solid N-((1S,9S)-4-chloro-9-ethyl-5-fluoro-9-hydroxyl-10,13-di(oxo)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)-2-hydroxyacetamide (5 mg).

[0165] The compounds prepared in Table II below were reacted and worked up in the same manner as in Example C518.

[0166] Table II [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6] [Table 4-7] [Table 4-8]

[0167] The prepared compounds in Table III below were synthesized from intermediate 12 or intermediate 13 using methods similar to C518, described above.

[0168] Table III [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] [Table 5-7]

[0169] C589 Method [ka] Step K: (S)-N-((1S,9S)-9-ethyl-5-fluoro-9-hydroxyl-4-methyl-10,13-di(oxo)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)-3-hydroxybutyroamide: (1S,9S) To a solution of 1-amino-9-ethyl-5-fluoro-9-hydroxyl-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-10,13-dione methanesulfonate (50 mg, 0.10 mmol, CAS: 169869-90-3) and 2 mL of DMF, (S)-3-hydroxybutyric acid (15.6 mg, 0.15 mmol) and HATU (57.9 mg, 0.15 mmol) were added, followed by 0.5 mL of DMF. o C, EtN (20.5 mg, 0.20 mmol) was added dropwise and the mixture was cooled to 0 o The mixture was stirred at room temperature for 2 h from C. The mixture was poured into 1 L of ice water, extracted with ethyl acetate (20 mLx3), washed with brine (20 mLx2), dried over Na2SO4, and concentrated. The residue was purified by preparative HPLC to give (S)-N-((1S,9S)-9-ethyl-5-fluoro-9-hydroxyl-4-methyl-10,13-di(oxo)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl)-3-hydroxybutyroamide (9.4 mg) as a yellow solid.

[0170] The compounds prepared in Table IV below were reacted and worked up in the same manner as in Example C589.

[0171] Table IV [Table 6-1] [Table 6-2] [Table 6-3] [Table 6-4] [Table 6-5] EXAMPLES

[0172] Preparation of the linker 2.1 Preparation of linker HX20113 [ka] HX20113 was synthesized by the general solid phase polypeptide synthesis method of Rink-amide-MBHA-resin. Fmoc is the protecting amino acid in the linking unit. The conjugation reagent is selected from HOBT, HOAt / DIC, DCC, EDCI or HATU. After synthesis, the resin was decomposed with trifluoroacetic acid. The product was purified by HPLC and lyophilized for use. Theoretical mass: 1207.59, Measured: [MH] - =1206.7.

[0173] Preparation of linker HX20111 [ka] HX20111 was synthesized by the general solid phase polypeptide synthesis method of Rink-amide-MBHA-resin. Fmoc is the protecting amino acid in the linking unit. The conjugation reagent is selected from HOBT, HOAt / DIC, DCC, EDCI or HATU. After synthesis, the resin was decomposed with trifluoroacetic acid. The product was purified by HPLC and lyophilized for use. Theoretical mass: 1383.70, Measured: [MH] - =1382.6. EXAMPLES

[0174] Preparation of linker-payload intermediate 3.1 Preparation of intermediate Mc-GGFG-Dxd The intermediate Mc-GGFG-Dxd can be purchased commercially or prepared by the methods described in EP 2907824. The compound can be used to prepare the linker-payload intermediate (compound of formula (I)) and can also be used to prepare the control ADC LC1184(8) and the control ADC LC1184(4) by direct conjugation with an antibody (which may be modified).

[0175] 3.2 Preparation of H0019 [ka] Synthesis of HX21008-a Weigh out 4.33 g of Fmoc-Gly-Gly-OH and 6.84 g of Pb(OAc) The mixture was placed in a 500 mL one-neck round-bottom flask. Anhydrous THF / toluene (120 / 40 mL) was added under a nitrogen gas atmosphere and dissolved by stirring. 1.16 mL of pyridine was then added to the reaction system. Under a nitrogen gas atmosphere, the reaction system was heated to 80°C and refluxed for 5 h. The reaction was monitored by sampling and measuring by HPLC.

[0176] The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with EA three times. The filtrates were combined and concentrated to dryness. Purification by column chromatography (PE:EA=100:0 to 50:100) afforded 2000 mg of the target product as a white solid, with a yield of 44%.

[0177] Synthesis of H0005-a 200 mg of HX21008-a was weighed and placed in a 100 ml one-neck round-bottom flask. Then, 15 ml of THF was added and dissolved by stirring. Next, H0005 (316 mg, 3.0 eq) and TsOH·H2O (15 mg, 0.15 eq) were added. The reaction system was kept at room temperature. The reaction was allowed to proceed overnight at RT. The reaction was monitored by sampling and measuring with TLC (PE / EA=1:1). The raw material essentially disappeared and a new spot appeared.

[0178] The reaction was quenched by adding saturated sodium bicarbonate solution. It was extracted with EA three times. The combined organic phase was washed with brine, dried over anhydrous magnesium sulfate and concentrated to give a crude product, which was purified by column chromatography (PE:EA=5:1-1:1) to give about 165 mg of the desired product as a colorless oil, with a yield of 60%. MS: [M+H] + =503.4. Synthesis of H0005-b 200mg of H0005-a was weighed and placed in a 100ml one-neck round-bottom flask. Then, 10ml of EtOH and 5ml of EA were added to completely dissolve it. Next, 40mg of palladium carbon was added to the reaction system under a nitrogen gas atmosphere, and nitrogen gas was passed through the reaction system three times. The reaction was kept under hydrogen gas atmosphere and stirred at room temperature for 0.5 h. The reaction was monitored by sampling and measuring by TLC (DCM / MeOH=10:1). The raw material essentially disappeared and a new spot appeared.

[0179] The reaction was filtered and the filter cake was washed with EA three times. The combined filtrate was concentrated to dryness to give 200 mg of the product as a white solid, the yield was 100%. The product was used directly in the next reaction without purification. [M+H] + =413.3. Synthesis of H0005 2.0 g of dichloro resin was weighed and placed in a peptide synthesis tube. DCM (10 ml) was added and allowed to swell at room temperature for 30 minutes. The solvent was removed by vacuum suction. The resin was washed twice with DCM, with a volume of 7 mL each time and a time of 1 minute. The solvent was removed by vacuum suction. Next, H0005-b (200 mg) was weighed and placed in a 50 ml centrifuge tube. DCM (about 10 ml) was added and the solid was dissolved by shaking. It was added to the above resin. It was stirred so that all the resin was immersed in the solution (if the resin was attached to the tube wall, wash the tube wall with a small amount of DCM). It was stirred for 4 to 5 hours. After the reaction was completed, an appropriate amount of methanol was added. It was stirred for 30 minutes. The solvent was removed by vacuum suction. The resin was washed once with DMF, once with methanol, once with DMF, once with ethanol, and twice with DMF, with a volume of 10 mL each time and a time of 1 minute. The solvent was removed by vacuum suction. Ninhydrin detection was performed on a small amount of dried resin. The resin was clear and colorless and the solution was pale yellow, indicating it was acceptable for the next step of coupling.

[0180] Deprotection was performed twice by adding 10 mL of ready-made 20% piperidine / DMF solution, each time for 10 min. After completion of the reaction, the solution was removed by vacuum suction. The resin was washed twice with DMF, once with methanol, once with DMF, once with ethanol, and twice with DMF, each time for 10 mL volume and 1 min time. The solvent was removed by vacuum suction. Ninhydrin detection was performed on a small amount of dried resin. Both the resin and the solution were deep blue in color.

[0181] 563 mg of Fmoc-Phe-OH and 197 mg of HOBt were added to a 50 mL centrifuge tube. Then, about 7 mL of DMF was added. The solid was dissolved by shaking. Then, 0.24 mL of DIC was added. Activation was performed for 10 to 30 minutes to obtain an activated reaction solution.

[0182] Three molar equivalents of the activation reaction solution were added to the resin. The resin was stirred so that it was completely immersed in the solution (if the resin was attached to the wall of the tube, the wall of the tube was washed with a small amount of DCM). The mixture was stirred for 2 to 3 hours. After the reaction was completed, the solvent was removed by vacuum suction. The resin was washed twice with DMF, once with methanol, once with DMF, once with ethanol, and twice with DMF, each time with a volume of 10 mL and a time of 1 minute. The solvent was removed by vacuum suction. A small amount of dried resin was subjected to ninhydrin detection. The resin was colorless and transparent, and the solution was pale yellow, suggesting that it was passed for the next step of coupling.

[0183] Deprotection was performed twice by adding 10 mL of ready-made 20% piperidine / DMF solution, each time for 10 min. After completion of the reaction, the solution was removed by vacuum suction. The resin was washed twice with DMF, once with methanol, once with DMF, once with ethanol, and twice with DMF, each time for 10 mL volume and 1 min time. The solvent was removed by vacuum suction. Ninhydrin detection was performed on a small amount of dried resin. Both the resin and the solution were deep blue in color.

[0184] 531 mg of Fmoc-Phe-OH and 197 mg of HOBt were added to a 50 mL centrifuge tube. Then, about 10 mL of DMF was added. The solid was dissolved by shaking. Then, 0.24 mL of DIC was added. Activation was performed for 10 to 30 minutes to obtain an activated reaction solution.

[0185] Three molar equivalents of the activation reaction solution were added to the resin. The resin was stirred so that it was completely immersed in the solution (if the resin was attached to the wall of the tube, the wall of the tube was washed with a small amount of DCM). The mixture was stirred for 2 to 3 hours. After the reaction was completed, the reaction solution was removed by vacuum suction. The resin was washed twice with DMF, once with methanol, once with DMF, once with ethanol, and twice with DMF, each time with a volume of 10 mL and a time of 1 minute. The solvent was removed by vacuum suction. A small amount of dried resin was subjected to ninhydrin detection. The resin was colorless and transparent, and the solution was pale yellow, suggesting that it was passed for the next step of coupling.

[0186] Deprotection was performed twice by adding 10 mL of ready-made 20% piperidine / DMF solution, each time for 10 min. After completion of the reaction, the solution was removed by vacuum suction. The resin was washed twice with DMF, once with methanol, once with DMF, once with ethanol, and twice with DMF, each time for 10 mL volume and 1 min time. The solvent was removed by vacuum suction. Ninhydrin detection was performed on a small amount of dried resin. Both the resin and the solution were deep blue in color.

[0187] In a 50 mL centrifuge tube, 462 mg of MC-OSu and 10 mL of DMF were added. The solid was dissolved by shaking. Then, 0.24 mL of DIEA was added to the resin. The resin was stirred so that it was completely immersed in the solution (if the resin was attached to the tube wall, the tube wall was washed with a small amount of DCM). The mixture was stirred for 2 to 3 hours. After the reaction was completed, the reaction solution was removed by vacuum suction. The resin was washed twice with DMF, once with methanol, once with DMF, once with ethanol, and twice with DMF, each time with a volume of 10 mL and a time of 1 minute. The solvent was removed by vacuum suction. A small amount of dried resin was subjected to ninhydrin detection. The resin was colorless and transparent, and the solution was pale yellow, suggesting that it passed the next step of coupling.

[0188] The resin was washed twice with 10 mL of methanol. Then, the solvent was completely removed by vacuum suction. The resin was taken out and weighed. A dissolution buffer was prepared in a 250 mL Erlenmeyer flask with a TFE / DCM ratio of 80% / 20% and a volume of 7-8 times the weight of the peptide resin. The dissolution buffer was added to the peptide resin and shaken evenly. The resin was completely immersed in the dissolution buffer and dissolved at room temperature for 2-3 hours. The dissolution buffer was then filtered through a simple filter made of a syringe, and the resin was washed with 1-2 ml of DCM and discarded. Then, 150 mL of pre-cooled anhydrous ether was added to the dissolution buffer, shaken evenly, and then left to stand for 20-30 minutes. Using a 50 mL centrifuge tube, the above system was centrifuged in a centrifuge at 3500 rpm for 3 minutes, and the supernatant was taken out and discarded. The solid was shaken with pre-chilled anhydrous ether, sonicated once, centrifuged at 3500 rpm for 3 minutes, and the supernatant removed and discarded. The solid was air-dried in the centrifuge tube overnight, then pre-purified to give 125 mg of product as a white solid, 40% yield. [M+H] + =645. 4. Synthesis of H0013 150 mg of raw material H0005 and 55 mg of TSTU were weighed and placed in a 10 mL one-neck round-bottom flask, and anhydrous DMF (3 mL) was added under a nitrogen gas atmosphere and stirred for 20 min. Next, 18 mg of TSN 00643 and 20 μl of DIEA were added in order to the reaction system. The mixture was stirred at room temperature under a nitrogen gas atmosphere for 2 h. The reaction was monitored by sampling and measuring by HPLC. The raw material peaks essentially disappeared and a new peak appeared.

[0189] The reaction mixture was purified and the target product was collected and lyophilized to give about 22 mg of a pale yellow solid product. [M+H] + =1062.7. Synthesis of H0019 Weigh out H0013 (30 mg) and place it in a 10 mL one-neck round-bottom flask. Add purified water (2 ml) was added. Stirred to dissolve. HX20111 (19.5 mg) in DMF (2 mL) was added to the reaction system and stirred. After overnight reaction, the reaction was monitored by HPLC until all the raw materials were converted to intermediates. Then, the reaction was cooled to 0-10°C and 0.5% LiOH solution was added to the reaction system while controlling the temperature until the pH value of the reaction system was about 12. The reaction was stirred for 20 min and the reaction was monitored by HPLC until all the intermediates were consumed, after which the reaction was quenched by adding 30% acetic acid (1.5 mL) to the reaction system.

[0190] The reaction system was purified by fractionation, and the target product was collected and lyophilized to obtain about 25 mg of a pale yellow solid product. [(M+3H) / 3] + =1182.3. 3.3 H0020, H0021, H0034 and H0035 Linker-payload intermediates H0020, H0021, H0034 and H0035 can be prepared using similar synthetic routes and reagents. Intermediates H0014, H0015, H0026 and H0032 were synthesized in a manner similar to H0013 and subsequently used in the synthesis of H0020, H0021, H0034 and H0035, respectively.

[0191] [ka] [ka] The LC-Ms data is shown in the table below. [Table 7] 3.4 Preparation of LB302-2-4 [ka] HX 20111 and intermediate MC-GGFG-Dxd (with a molar ratio of about 1:2) were weighed and dissolved in water and DMF, respectively, then thoroughly mixed to obtain a mixture, which was reacted at 0-40°C for 0.5-30 h. After the reaction was completed, an appropriate amount of Tris-Base solution or other solution that promotes the ring-opening reaction was directly added to the reaction mixture, and then reacted at 0-40°C for another 0.2-20 h. After the reaction was completed, the product was purified by semi-preparative / preparative HPLC and lyophilized to obtain linker-payload intermediate LB 302-2-4. Theoretical mass: 3486.52, Measured mass: [(M+3H) / 3] + =1163.3.

[0192] 3.5 Preparation of LB302-2-1 LB302-2-1 can be prepared by similar synthetic routes and reagents.

[0193] [ka] EXAMPLES

[0194] Construction of antibody expression vectors, antibody expression, purification and identification 4.1 Modified anti-human HER2 antibody Ab0001-LCCT L Preparation of -HC Antibody Ab0001-LCCT L -HC (light chain SEQ ID NO: 9, heavy chain: SEQ The expression plasmid for antibody Ab0001-LCCT (ID NO:10) is constructed as follows: L -HC sequence: Based on the amino acid sequence of trastuzumab, GA at the C-terminus of the light chain LPETGG was introduced, where LPETGG is the recognition sequence of the ligase donor substrate and GA is the spacer sequence. The plasmid was transfected into CHO cells, a cell population was established, and a high-expressing cell population was screened, which was cultured according to the culture process of trastuzumab in a 5-10L reactor, and the supernatant was collected.

[0195] 4.2 Antibody Ab0001-LCCT L -HC purification Ab0001-LCCT L -HC was purified using MabSelect affinity chromatography. The purification was performed using a standard process combining HPLC with Sepharose S cation exchange chromatography, and the purified product was purified in the original trastuzumab drug buffer (5 mM Histidine-HCl, 2% Trehalose, 0.009% Polysorbate 20, pH 6.0) and frozen in equal aliquots.

[0196] 4.3 Antibody Ab0001-LCCT L -HC mass control Antibody Ab 0001-LCCT purified by SDS-PAGE L -HC purity was 98.5%, and the content of high molecular weight polymers in the sample was detected by SEC-HPLC to be less than 0.4%, and the content of endotoxin was less than 0.098 EU / mg.

[0197] 4.4 Preparation of other modified anti-human antibodies Based on a similar method, terminal modifications based on ligase recognition sequences were introduced into the C-terminus of the light chain and / or heavy chain of trastuzumab to obtain modified antibodies.

[0198] The modified anti-human HER2 antibody based on Ab0001 (trastuzumab) is as shown in the following table. In the terminal modification sequence, LPETGG is a recognition sequence for the ligase donor substrate, and GA is a spacer sequence.

[0199] Modified anti-human HER2 antibodies [Table 8] EXAMPLES

[0200] Preparation of antibody-small molecule conjugates 5.1 The linker-payload intermediates are each site-specifically conjugated to an antibody by a ligase to form an ADC. Methods for the conjugation reaction can be found in WO2015165413. The ADCs generated are shown in the table below. [Table 9]

[0201] 5.2 Control ADCs LC 1184(8) and LC 1184(4) were synthesized by cloning the intermediate Mc-GGFG-Dxd with Ab 0001-LCCT L -HC directly bonded (Cys Conjugation reactions are well known in the art. LC 1184(8) is prepared by introducing eight Mc-GGFG-Dxds via reduced interchain cysteines. LC 1184(4) is prepared by introducing eight Mc-GGFG-Dxds via reduced interchain cysteines. The four Mc-GGFG-Dxd are introduced by:

[0202] Example 1: Effect of small molecules on cell proliferation Study Objective: This experiment was conducted to evaluate the effect of small molecule compounds on the proliferation of HER2-rich tumor cell line SK-BR-3 by measuring cell activity using CellTiter-Glo, and to analyze the effect of small molecule compounds on tumor cell proliferation.

[0203] Materials and Equipment PBS: Gibco, Cat#10010-023); Trypsin: Gibco, Cat#25200056); FBS: Gibco, Cat#10270-106); CellTiter-Glo® Luminescent Cell Viability Assay; Promega, Cat#G7573); McCoy's 5A: Gibco, Cat#16600-082); L15: Hyclone, Cat#SH30525.01); DMEM: Gibco, Cat#11995-065). 96-well plates Corning / 3603; 96-well deep well plates: Thermo / 278743; 15 mL microcentrifuge tubes: Thermo / 339650; 1.5 mL microcentrifuge tubes: Beaver.

[0204] Cell inoculation - day 1 (1) Microscopic examination of cells (2) Digestion: Digested with 2 mL of 0.25% trypsin for 3 minutes. (3) Centrifugation: 1000rpm, 5min; (4) Cell counting A. Cell Dilution: B. Cell inoculation: 100 μl / well C. Incubate at 37°C, 5% CO2, overnight Cellular testing

[0205] (1) (Microscopic examination) (2) Preparation of drugs: A. Preparation of Sample Preparation Buffer: Prepare the required amount of Sample Preparation Buffer using test cell culture medium (10% FBS). B. Sample preparation: Samples were diluted from the first concentration to the desired concentration in a 96 deep well plate.

[0206] Test compounds: Prepared in cell culture medium at ten final concentrations: 1000, 200, 40, 8, 1.6, 0.32, 0.064, 0.0128, 0.00256 and 0.000512 nM.

[0207] Positive control puromycin: A stock solution of 2.5 mg / ml was used and diluted in cell culture medium. A 250-fold dilution was performed, followed by a 2-fold dilution to give a test concentration of puromycin of 5 μg / ml when the compound was administered.

[0208] (3) Compound administration: Compounds were administered in triplicate at each concentration in the dilution series, 100 μl / well.

[0209] (4) After administering the drugs, the cells were incubated in an incubator for 120 hours.

[0210] Cellular activity test (1) Preparation of detection reagent: CellTiter-Glo Luminescent Cell The ll Viability Assay reagent was allowed to warm to room temperature while being protected from light.

[0211] (2) Cell preparation: The test cells were removed from the incubator and equilibrated at room temperature (25° C.) for 30 minutes.

[0212] (3) ATP measurement: The medium was discarded and 100 μl / well of DMEM was added, and 50 μl / well of CTG was added to a 96-well plate. The plate was shielded from light with aluminum foil and shaken at 200 rpm at room temperature for 10 minutes using a vortex mixer.

[0213] (4) Measurement program: After setting the program, the black-walled transparent bottom plate was placed on the instrument without the cover.

[0214] (5) Data collection 5. Data Processing and Analysis Data was processed using GraphPad software. A four-parameter curve model was used to plot the cell growth inhibition rate versus the concentration of the control or test sample, and data fitting was performed to obtain the R 2 (Rounded to 4 significant digits ) and IC 50(Round to 4 significant digits) or EC 50 If necessary, the relative biological activity or specific activity of sample A was calculated. Dxd was used as the reference sample for calculating the specific activity.

[0215] Cell proliferation inhibition rate (%) = (luminescence value of drug-treated group - luminescence value of puro group) / (luminescence value of blank control group - luminescence value of puro group) x 100 (puro group is the puromycin-treated group). Specific activity of sample (%) = (IC of control sample 50 Value / IC of test sample 50 value) × 100 Specific activity of control sample (%) = (IC of control sample 50 Value / IC of previous test sample 50 value) × 100 6. Result verification R 2 Values ​​≥ 0.950, CV% ≤ 30% between duplicate wells.

[0216] result: The results are shown in the table below. [Table 10] Example 2: Effect of HER2-targeting conjugates on cell proliferation Study Objective: To evaluate the effect of ADC on the proliferation of two HER2 high tumor cell lines SK-BR-3, NCI-N 87, and HER2 negative tumor cell line MDA-MB-468 by measuring the detection cell activity using CellTiter-Glo, and to analyze the effect of ADC on tumor cell proliferation.

[0217] Materials and Equipment PBS: Gibco, Cat#10010-023); Trypsin: Gibco, Cat#25200056); FBS: Gibco, Cat#10270-106); CellTiter-Glo® Luminescent Cell Viability Assay: Promega, Cat#G7573); McCoy's 5A: Gibco, Cat#16600-082); L15: Hyclone, Cat#SH30525.01); DMEM: Gibco, Cat#11995-065). 96-well plates Corning / 3603; 96-well deep well plates: Thermo / 278743; 15 mL microcentrifuge tubes: Thermo / 339650; 1.5 mL microcentrifuge tubes: Beaver.

[0218] Cell inoculation - day 1 (1) Microscopic examination of cells (2) Digestion: Digested with 2 mL of 0.25% trypsin for 3 minutes. (3) Centrifugation: 1000rpm, 5min; (4) Cell counting A. Cell Dilution: B. Cell inoculation: 100 μl / well C. Incubate at 37°C, 5% CO2, overnight

[0219] Cellular testing (1) Microscopic examination (2) Preparation of drugs: A. Preparation of sample preparation buffer: Mix the required amount of test cell culture medium (10% FBS) A sample preparation buffer was prepared. B. Sample preparation: Samples were diluted from the first concentration to the desired concentration in a 96 deep well plate.

[0220] Test samples: Prepared by dilution in cell culture medium to ten final concentrations: 200, 40, 8, 1.6, 0.32, 0.064, 0.0128, 0.00256, 0.000512 and 0.0001024 nM.

[0221] Positive control puromycin: A stock solution of 10 mg / ml was used and diluted in cell culture medium. A 100-fold dilution was performed, followed by a 10-fold dilution to give a test concentration of puromycin of 5 μg / ml when compounds were administered.

[0222] (3) Compound administration: Compounds were administered in triplicate at each concentration in the dilution series, 100 μl / well.

[0223] (4) After administering the drugs, the cells were incubated in an incubator for 120 hours.

[0224] Cellular activity test (1) Preparation of detection reagent: The CellTiter-Glo Luminescent Cell Viability Assay reagent was warmed to room temperature while being protected from light.

[0225] (2) Cell preparation: The test cells were removed from the incubator and equilibrated at room temperature (25° C.) for 30 minutes.

[0226] (3) ATP measurement: The medium was discarded and 100 μl / well of DMEM was added, and 50 μl / well of CTG was added to a 96-well plate. The plate was shielded from light with aluminum foil and shaken at 200 rpm at room temperature for 10 minutes using a vortex mixer.

[0227] (4) Measurement program: After setting the program, the black-walled transparent bottom plate was placed on the instrument without the cover.

[0228] (5) Data collection 5. Data Processing and Analysis Data was processed using GraphPad software. A four-parameter curve model was used to plot the cell growth inhibition rate versus the concentration of the control or test sample, and data fitting was performed to obtain the R 2 (Rounded to 4 significant digits ) and IC 50 (Round to 4 significant digits) or EC50 obtained.

[0229] Cell proliferation inhibition rate (%) = (luminescence value of drug-treated group - luminescence value of puro group) / (luminescence value of blank control group - luminescence value of puro group) x 100 (puro group is the puromycin-treated group). 6. Result verification R 2 Values ​​≥ 0.950, CV% ≤ 30% between duplicate wells.

[0230] result: The results are shown in the following table and in Figures 1, 2 and 3. [Table 11]

[0231] In HER2-highly expressing SK-BR-3 and NCI-N 87, the conjugates (CH-2-589, CH-2-593, CH-2-518, LC302-2-1(4) and LC302-2-4(4)) showed remarkable efficacy. The IC 50 The value is smaller than that of the small molecule payload Dxd. In HER2-negative cells, the conjugate showed minimal effect. No cytotoxicity was observed in HER2-negative cells MDA-MB-468, proving the stability of the conjugate and reducing off-target release of the payload, resulting in good safety. From the above, it is clear that the conjugate showed HER2-dependent cytotoxic activity in a dose-dependent manner, good targeting ability, remarkable efficacy and good safety.

[0232] Efficacy example 3: Evaluation of bystander killing effect Purpose of the study: In a co-culture system of HER2-positive tumor cell line SK-BR-3 and HER2-negative tumor cell line MDA-MB-468, we measured the bystander killing activity of ADCs (CH-2-589, CH-2-593, CH-2-518 and LC302-2-4(4)) against MDA-MB-468 cells, and compared them with a control ADC with a structure similar to DS8201a. (LC1184 (8)) and its bystander killing effect was compared.

[0233] Materials and Equipment L15: Hyclone, SH30525.01; McCoy's 5A: Gibco, 16600-082; FBS: Gibco, 10099-141; Firefly luciferase reporter gene assay kit: Beyotime, RG006; 50ml centrifuge tubes: corning, 430829; 15ml centrifuge tubes: corning, 430791; 96-well plates: corning, 3599; CO2 cell incubator: Th ermo; centrifuge: Thermos, L550; microscope: Nikon, ISZ; cell counter: Countstar, IC1000; Cytation3 plate reader: BioTek, Cytation3; HTX multimode microplate reader: BioTek, Synergy HTX; SK-BR-3: ATCC, HTB-30; MDA-MB-468-Luc-GFP: homemade using lentiviral infection.

[0234] Experimental Method 1) Cell collection and counting.

[0235] 2) Set the cell density to 1*10 5 Adjusted to cells / ml 3) A cell mixture was prepared with a ratio of SKBR3:MDA-MB-468-Luc-GFP=4:1, 5 ml.

[0236] Cell inoculation: 1*10 4 Cells / well, 100 μl / well Test samples: Prepared and diluted in cell culture medium to three final concentrations: 50, 10 and 1 nM.

[0237] 4) Drugs were administered on day 2, 100 μl / well.

[0238] 5) The cells were cultured in a 37°C, 5% CO2 incubator for 120 hours.

[0239] (1) Wash with PBS to remove dead cells and detect them with a Cytation3 plate reader. (2) Hekiunten Luciferase Reporter Gene Assay Kit: Dissolved in 100 μl of dissolution buffer in a 37°C incubator for 10 minutes. Centrifuged at 2000 rpm for 5 minutes. Removed 100 μl of the supernatant. Added 100 μl of substrate. Chemiluminescence was detected by a microplate reader (gain: 200).

[0240] result: Two methods (GFP fluorescence counting and luciferase substrate luminescence) were used to detect the bystander killing effect (Figures 4a, 4b and 5).

[0241] All of the conjugates (CH-2-593, CH-2-589, CH-2-518, and LC302-2-4 (4)) showed significant bystander killing during detection using these two methods. CH-2-593 showed a bystander killing effect comparable to or higher than that of LC1184 (8).

[0242] Effect Example 4 In vivo evaluation of conjugates 4.1 JIMT-1 human breast cancer xenograft model 5x10 6 JIMT-1 human breast cancer cells (HER2 medium) were cultured in a SCID Beige model. The tumors were inoculated subcutaneously into the right armpit of each mouse. After 7 days, the mean tumor volume was 142 mm 3 If it reaches the Mice were distributed and administered LC1184(8) and five other different conjugates intravenously at a dose of 5 mg / kg. Tumor volumes were measured twice weekly with calipers. LC1184(8) showed higher potency than LC1184(4), indicating that a higher DAR results in higher potency when the payload is the same. The potency of LC302-2-1(4) and LC302-2-4(4) is higher than LC1184(8) (Figure 6). The conjugates of the present invention achieve higher potency with a lower DAR.

[0243] 4.2 Capan-1 human pancreatic cancer xenograft model (1) 5x10 6 Capan-1 human pancreatic cancer cells (HER2 low) were transfected into BALB / c nude mice. Xenograft models were obtained by subcutaneous inoculation into the right flank of mice. After 8 days, the mean tumor volume was 178 mm 3 When the IL-16 receptor agonist (IL-16 receptor agonist) was detected in tumor-bearing mice, LC1184 (8) and five other different conjugates were Tugate was administered intravenously at a dose of 5 mg / kg. Tumor volumes were measured twice weekly with a caliper. LC1184(8) showed higher potency than LC1184(4). LC302-2-1(4) and LC302-2-4(4) showed potency comparable to LC1184(8) (Figure 7).

[0244] 4.3 Capan-1 human pancreatic cancer xenograft model (2) Study Objective: The objective of this study was to evaluate the in vivo antitumor efficacy of CH-2-589, CH-2-593, CH-2-518 and LC302-2-4(4) during treatment of subcutaneous Capan-1 human pancreatic cancer xenograft model in female BALB / c nude mice.

[0245] Study design: Cell culture: Capan-1 tumor cells (ATCC-HTB-79) were cultured at 37°C in air. The cells were incubated in IM filled with 20% fetal bovine serum, 1% antibiotic-antimycotic in an atmosphere of 5% CO2. The cells were maintained ex vivo as monolayer cultures in DM. Tumor cells were routinely subcultured twice a week by trypsin-EDTA treatment. Cells grown in the logarithmic growth phase were harvested and counted for tumor inoculation.

[0246] Animals: Female BALB / c nude mice, 6-8 weeks old, weighing approximately 18-22g. The study requires a total of 48 animals (30 plus 60%) to be purchased from Shanghai Lingchang Laboratory Animal Co., LTD or other certified suppliers.

[0247] Tumor inoculation: For each mouse, inoculate Capan-1 tumor cells (5 × 10 6 ) was subcutaneously injected into the right armpit to promote tumor growth. The average tumor volume is about 150-200 mm 3 If the animals reach Treatment was initiated to conduct the efficacy study. The test article doses and animal numbers for each group are shown in the experimental design table below.

[0248] Groups and treatments [Table 12]

[0249] Experimental times were adjusted based on tumor volume.

[0250] Animal Husbandry: To allow the animals to adapt to the laboratory environment, there is an adaptation period of approximately one week from the animals' arrival in the laboratory before tumor inoculation. Mice were maintained in a specific pathogen-free environment, in single ventilated cages (three mice per cage). All cages, mats and water were disinfected before use. When working in the mouse room, researchers wear laboratory coats and latex or ethylene gloves. Each cage was labeled with a card indicating the animal quantity, sex, breed, date of receipt, treatment, study number, group number and treatment start date. Cages containing food and water are changed twice weekly. The desired conditions of the animal room environment and photoperiod are as follows: Temperature: 20~26°C Humidity: 40~70% Light / dark cycle: 12 hours light, 12 hours dark Dietary material: All animals had free access to a certified test animal commercial standard diet. Maximum allowable concentrations of contaminants in the diet were controlled by the manufacturer and analyzed regularly. Autoclaved municipal tap water suitable for human consumption was available ad libitum to the animals. Dietary material was deemed free of known contaminants that could affect tumor growth.

[0251] Grouping: Before treatment began, all animals were weighed and tumor volumes were measured. Because tumor volume can affect the efficacy of any given treatment, mice were grouped using Excel-based randomization software and stratified randomization was performed based on their tumor volume. This ensured that all groups were comparable at baseline.

[0252] Observations: The protocol and all amendments or procedures related to the care and use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of WuXi AppTec before the start of the study. During the study, the care and use of animals was performed in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) regulations. After inoculation, animals were checked daily for morbidity and mortality. At the time of routine monitoring, animals were checked for tumor growth and any effects of treatment on normal behavior, such as motility, food and water consumption, weight gain / loss, eye / hair fading, and any other abnormal effects. Mortality and observed clinical signs were recorded based on the number of animals in each subset.

[0253] Endpoints: The primary endpoint was to observe whether the tumor growth could be delayed or whether the mice could be cured. The tumor size was measured twice weekly in two dimensions with calipers and the volume was calculated according to the formula: V = 0.5a × b 2 Calculate in mm 3 The tumor size is expressed as TGI(%)=[1-(Ti-T0) / (Vi-V0)]×100, where a and b are the long and short diameters of the tumor, respectively. The tumor size is then used to calculate the TGI(%) and relative tumor growth rate T / C(%) values. The TGI of each group is calculated by the formula TGI(%)=[1-(Ti-T0) / (Vi-V0)]×100, where Ti is the average tumor volume of the treatment group on a given day, T0 is the average tumor volume of the treatment group on the first day of treatment, Vi is the tumor volume of the vehicle control group on the same day as Ti, and V0 is the average tumor volume of the vehicle group on the first day of treatment.

[0254] The T / C (%) value for each group was T / C% = T RTV / C RTV × 100%, (TRTV : relative mean tumor volume (RTV) of the treatment group, C RTV :T RTV vs. vehicle control on the same day The relative tumor volume (RTV) of each group is RTV = V t / V0, where V0 is the tumor volume on the first day of treatment and V t is the tumor volume on a given day.

[0255] end: 1) Weight Loss: Animals exhibiting a 20% weight loss on any one day will be humanely sacrificed or a veterinarian will be contacted.

[0256] 2) Tumor burden: Tumor burden is 3,000mm 3 Tumor volume should not exceed 3,000 mm 3 Once this is reached, the animals are immediately sacrificed.

[0257] Ulceration: If ulceration of the tumor occurs, the following procedure is applied: Animals with ulcerated tumors are monitored at least three times per week, increasing frequency up to once daily depending on clinical signs.

[0258] Ulcerated tumors that do not have a crust should be cleaned with an appropriate wound cleansing solution (e.g., Novalsan). An antibiotic cream may be applied to the ulcer / lesion only if directed by a veterinarian.

[0259] Criteria for euthanasia include pathology (one or more of the following): If the wound does not heal or form a scab within a week, If the diameter is more than 5 mm, If hollowing occurs, There are signs of infection (e.g., the presence of pus) or bleeding, or the animal shows signs of discomfort (e.g., excessive licking and chewing at the site) or general signs of illness (lethargy, reduced activity, food refusal). This includes cases where the animal shows signs of poor nutrition, decreased body condition or weight loss. Contact your veterinarian to discuss any possible exceptions.

[0260] 3) Clinical signs: If an animal is found moribund, it must be euthanized (certified by the IACUC with sufficient justification as must be included in the protocol and with warmed subcutaneous fluids, dietary supplements placed near the animal so that the animal has access to food). (Excluding cases where additional supportive care is provided, such as placing gel food cups or placing cages on heating pads for supplemental heat. Note: Moribund status indicates the animal is unlikely to survive.) Please contact your veterinarian with questions regarding these endpoints.

[0261] Clinical manifestations of the disease may include: Shrink yourself. Persistent recumbency and lack of response to handling or other stimuli. Signs of severe organ or system failure. Losing weight. Hypothermia. CNS defect convulsions. Respiration: Rapid breathing, labored breathing, coughing, rales. GI: Diarrhea lasting more than 2 days, jaundice.

[0262] Any animals exhibiting the above clinical problems will be humanely sacrificed with CO2.

[0263] In cases of unexpected death, no autopsy will be performed.

[0264] Statistical analysis: For comparisons between two groups, an independent samples t-test was used. For comparisons between three or more groups, a one-way analysis of variance (ANOVA) was performed. If a significant F-statistic (ratio of treatment variance to error variance) was obtained, multiple comparisons were performed after ANOVA. All data were analyzed using SPSS 17.0. P<0.05 was considered statistically significant.

[0265] result: All of the conjugates exhibited significant tumor-suppressing effects (FIGS. 8a and 8b).

[0266] NCI-N87 human gastric cancer xenograft model Study Objective: The objective of this study was to evaluate the in vivo antitumor efficacy of CH-2-589, CH-2-593, CH-2-518 and LC302-2-4(4) during treatment of subcutaneous NCI-N87 human gastric cancer xenograft model in female BALB / c nude mice.

[0267] Study design: Cell culture: NCI-N87 tumor cells (ATCC, Manassas, VA, cat#CRL-5822) were cultured at 37 °C in an atmosphere of 5% CO in air, with 10% fetal bovine serum, 1 The tumor cells were maintained in vitro as monolayer cultures in RPMI 1640 medium supplemented with 100% antibiotic-antimycotic. Tumor cells were routinely subcultured twice a week by trypsin-EDTA treatment. Cells grown in the logarithmic growth phase were harvested and counted for use in tumor inoculation.

[0268] Animals: Female BALB / c nude mice, 6-8 weeks old, weighing approximately 18-22g. The study requires a total of 36 animals (30 plus 20%), which are provided by Shanghai Lingchang Laboratory Animal Co., LTD or other certified institutions. Purchase from approved suppliers.

[0269] Tumor inoculation: For each mouse, inoculate 10 × 10 NCI-N87 tumor cells in 0.2 mL of PBS containing Matrigel (1:1). 6 ) was subcutaneously injected into the right armpit to promote tumor growth. The average tumor volume was approximately 150–200 mm 3 If the animals reach Treatment was then initiated to conduct the efficacy study. The test article administration and animal numbers for each group are shown in the experimental design table below.

[0270] Groups and treatments [Table 13]

[0271] Experimental times were adjusted based on tumor volume.

[0272] result: All the conjugates exhibited significant tumor-suppressing effects (FIGS. 9a and 9b).

[0273] Effect Example 5: In vitro serum stability of the conjugate For in vitro serum stability studies, conjugates LC302-2-1 (4), LC302-2-4 (4) and LC1184 (8) were inoculated into mixed human serum at 37°C, respectively. At 0, 24, 48 and 96 hours, the conjugates were captured with antigen, then deglycosylated with glycosidase and dissociated with acid. The supernatants were collected and centrifuged, followed by detection by high-resolution LC-MS to determine the DAR.

[0274] LC302-2-1(4) and LC302-2-4(4) are highly stable after 96 hours of incubation in serum. There was no observed decrease in the DAR of LC302-2-1(4) and LC302-2-4(4) after 96 hours of incubation. However, the DAR of LC1184(8) decreased from 7.8 to 2.6 after 96 hours of incubation (Figure 10). The stability of the linker indicates that more payload is delivered to the target tumor and the release of off-target free payload is reduced, improving the therapeutic index. [Sequence table] SEQ ID NO: 1: Ab0001-LCCTL-HC LCDR1 RASQDVNTAVA SEQ ID NO: 2: Ab0001-LCCTL-HC LCDR2 SASFLYS SEQ ID NO: 3: Ab0001-LCCTL-HC LCDR3 QQHYTTPPT SEQ ID NO: 4: Ab0001-LCCTL-HCHCDR1 DTYIH SEQ ID NO: 5: Ab0001-LCCTL-HCHCDR2 RIYPTNGYTRYADSVKG SEQ ID NO: 6: Ab0001-LCCTL-HCHCDR3 WGGDGFYAMDY SEQ ID No. 7: Ab0001-LCCT L -HC light chain variable domain: DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTV SEQ ID NO: 8: Ab0001-LCCT L -HC Heavy Chain Variable Domain: EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSSEQ ID No. 9: Ab0001-LCCT L -HC light chain full length: DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGALPETG SEQ ID No. 10: Ab0001-LCCT L -HC Heavy Chain Length: EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Claims

1. A compound of formula (I) 【Chemistry 1】 Where: opSu is 【Chemistry 2】 or 【Chemistry 3】 and R 0 is C 1~10 is an alkyl group, n is any integer from 2 to 20; k1 and k2 are independently an integer from 1 to 7; i is an integer from 1 to 100; j is an integer from 1 to 100; P1 and P2 independently have a payload of the structure shown in (i'), 【Chemistry 4】 Where: a is 0 or 1; p1 * Carbon atom with p2 attached * each carbon atom marked with is an asymmetric center, and said asymmetric center is in the S configuration, the R configuration or is racemized; L 1 is C 1~6 alkylene groups, unsubstituted or selected from halogen, —OH and Bi-NH 2 and is substituted by one substituent selected from M is -CH 2 -, -NH- or -O-; L 2 is C 1-3 is an alkylene group, R 1 and R 2 are each independently hydrogen, C 1~6 Alkyl groups, halogens and C 1~6 The compound selected from the group consisting of alkoxy groups.

2. It has a structure shown in formula (I-1), 【Chemistry 5】 Where: P1, P2, R 0 , opSu, n, i and j are as defined in claim 1. The compound according to claim 1 .

3. In formula (i′), L 1 is C 1~6 Straight chain alkylene group, C 1~6 Branched chain alkylene group, C 3~6 Cycloalkyl C groups and 3~4 Cycloalkyl Group -C 1~2 straight chain alkylene groups, each of which is independently unsubstituted or selected from the group consisting of halogen, —OH and —NH. 2 One selected from is substituted by a substituent, Preferably, L 1 is C 1~4 Straight chain alkylene group, C 1~4 Branched chain alkylene group, C 3~4 Cycloalkyl and cyclopropyl-methylene, each of which is independently unsubstituted or substituted with halogen, —OH and —NH. 2 Substituted by one substituent selected from It has been Preferably, L 1 is -CH 2 -, -C 2 H 4 --, 【Chemistry 6】 each of said groups is independently unsubstituted or selected from the group consisting of halogen, —OH and —NH 2 and is substituted with at least one substituent selected from More preferably, L 1 is -CH 2 --, 【Chemistry 7】 where "#" indicates the position of attachment to the carbonyl group, More preferably, L 1 is -CH 2 --, 【Chemistry 8】 where "#" indicates the position of attachment to the carbonyl group, In particular, L 1 is -CH 2 --, 【Chemistry 9】 and 【Chemistry 10】 where "#" indicates the position of attachment to the carbonyl group, and / or 3. The compound according to claim 1 or 2, wherein halogen is selected from F, Cl and Br.

4. In formula (i′), M is -CH 2 -, -NH- or -O-; L 2 Ha-C 2 H 4 -or- M is -CH 2 - and L 2 Ha-CH 2 - according to any one of claims 1 to 3, compound.

5. In formula (i′), p1 * The carbon atom marked with is in the S configuration or racemized, preferably in the S configuration. Yes and / or p2 * The carbon atom marked with is in the S configuration or racemized, preferably in the S configuration. The compound according to any one of claims 1 to 4.

6. In formula (i′), R 1 and R 2 are each independently hydrogen, C 1~3 Alkyl groups, halogens and C 1~3 alkoxy groups, Preferably, R 1 and R 2 are each independently CH 3 -, F, Cl, Br and CH 3 O-, More preferably, R 1 is CH 3 - and Cl; and / or R 2 is F, More preferably, a is 0; R 1 is Cl, R 2 is F and L 1 is -CH 2 --, 【Chemistry 11】 Alternatively, a is 0; R 1 is CH 3 - and R 2 is F and L 1 teeth, 【Chemistry 12】 where "#" indicates the position of attachment to the carbonyl group; or a is 1; R 1 is CH 3 - and R 2 is F and L 1 teeth 【Chemistry 13】 M is O, and L 2 Ha-C 2 H 4 - according to any one of claims 1 to 5, compound.

7. The payload is 【Chemistry 14-1】 【Chemistry 14-2】 is selected from Preferably, 【Chemistry 15】 is selected from More preferably, 【Chemistry 16】 is selected from especially, 【Chemistry 17】 The compound according to any one of claims 1 to 6, selected from:

8. R 0 is C 1~6 is an alkyl group, preferably C 1~3 an alkyl group, in particular a methyl group, and / or n is an integer from 2 to 5, in particular 3, and / or k1 and k2 are independently 1 or 3 or 5, in particular 5; i is independently an integer from 1 to 20, preferably from 1 to 12, more preferably from 2 to 8, in particular 4; and / or A compound according to any one of claims 1 to 7, wherein j is independently an integer from 1 to 20, preferably 1 to 12, more preferably 8 to 12, particularly 8 or 12, especially 12. 【Request 9】 【Chemical 18-1】 【Chemistry 18-2】 The compound according to any one of claims 1 to 8, which is selected from:

10. Having the structure shown in formula (II), 【Chemistry 19】 Where: A is an antibody or antigen-binding fragment thereof, said antibody or antigen-binding fragment thereof being preferably modified to modify (Gly) in the compound of formula (I). n Binding to the part, z is an integer from 1 to 20, preferably from 1 to 4, in particular 2; P1, P2, R 0 , opSu, n, k1, k2, i and j are any of claims 1 to 8. A conjugate as defined in paragraph 1.

11.

20. The conjugate of claim 10, which is selected from:

12. (i) The antibodies include anti-CD19 antibodies, anti-CD20 antibodies, anti-CD22 antibodies, anti-CD25 antibodies, anti-CD30 / TNFRSF8 antibodies, anti-CD33 antibodies, and anti-CD37 antibodies. , anti-CD44v6 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD71 antibody, anti-CD74 antibody, anti-CD79b antibody, anti-CD117 / KITk antibody, anti-CD 123 antibody, anti-CD138 antibody, anti-CD142 antibody, anti-CD174 antibody, anti-CD227 / MUC1 antibody, anti-CD352 antibody, anti-CLDN18.2 antibody, anti- DLL3 antibody, anti-ErbB2 / HER2 antibody, anti-CN33 antibody, anti-GPNMB antibody, anti-ENPP3 antibody, anti-Nectin-4 antibody, anti-EGFRvIII antibody body, anti-SLC44A4 / AGS-5 antibody, anti-CEACAM5 antibody, anti-PSMA antibody, anti-T IM1 antibody, anti-LY6E antibody, anti-LIV1 antibody, anti-Nectin4 antibody, anti-SLITRK6 antibody, anti-HGFR / cMet antibody, anti-SLAMF7 / CS1 antibody, anti-EGFR antibody, anti-BCMA antibody, anti-AXL antibody, anti-NaPi2 B antibody, anti-GCC antibody, anti-STEAP1 antibody, anti-MUC16 antibody, anti-Mesothelin antibody, anti-ETBR antibody, anti-EphA2 antibody, anti-5T4 antibody, anti-FOLR1 antibody, anti-LAMP1 antibody, anti-Cadherin6 antibody, anti-F GFR2 antibody, anti-FGFR3 antibody, anti-CA6 antibody, anti-CanAg antibody, anti-integrin αV antibody, anti-TDGF1 antibody, anti-Ephrin A4 antibody, anti-TROP2 antibody, anti-PTK7 antibody, anti-NOTCH3 antibody, anti-C4.4A antibody, anti-FLT3 antibody, anti-B7H3 / 4 antibody, anti-Tissue Factor antibody or anti-ROR1 / 2 antibody, preferably anti-HER2 antibody, anti-FGFR3 antibody, anti-Trop2 antibody, anti-HER3 antibody or anti-FRα antibody, More preferably, the antibody is an anti-HER2 antibody, preferably an anti-human HER2 antibody, more preferably trastuzumab; and / or (ii) G in the compound of formula (I) defined in claim 1 n The part is the a of ligase. the antibody is modified to include a recognition sequence for a ligase donor substrate, thereby forming a G n Partial Combined, Preferably, (a) the ligase is a Sortase enzyme selected from Sortase A, Sortase B, Sortase C, Sortase D and Sortase L. plantarum, preferably from Staphylococcus aureus Sortase A from S. aureus, and / or (b) the ligase donor substrate recognition sequence is LPXTGJ, where J is absent or G m wherein G is glycine, m is an integer from 1 to 10, and X is any natural or non-natural and / or LPXTG is G n Binds to LPXTG n The conjugate of claim 10 or 11,

13. A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the conjugate according to any one of claims 10 to 12 and at least one pharma- ceutically acceptable carrier.

14. 14. The pharmaceutical composition of claim 13, wherein the drug / antibody ratio (DAR) of the conjugate is an integer or non-integer between 1 and 8, in particular an integer or non-integer between 3 and 4.

15. 15. Use of a conjugate according to any one of claims 10 to 12 or a pharmaceutical composition according to claim 13 or 14 in the manufacture of a medicament for treating a disease, said disease being a tumor or an autoimmune disease, preferably a tumor comprising HER2-positive tumor cells.

16. the tumor comprising HER2-positive tumor cells further comprises HER2 low expressing tumor cells; The use according to claim 15, wherein the HER2 expression level of the HER2 low-expressing tumor cells is lower than that of the HER2-positive tumor cells.

17. having the structure shown in formula (i), 【Chemistry 21】 Where: a, p1 * Carbon atom with p2 * A carbon atom with L 1 , M., L. 2 , R 1 and R 2 is as defined in any one of claims 1 to 7, or a pharma- ceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite or prodrug thereof. 【Request 18】 【Chemical 22-1】 【Chemistry 22-2】 is selected from Preferably, 【Chemistry 23】 is selected from More preferably, 【Chemistry 24】 is selected from especially, 【Chemistry 25】 18. The compound of claim 17, which is selected from:

19. A compound of formula (1), 【Chemistry 26】 Where: k is an integer from 1 to 7, preferably 1 or 3 or 5, in particular 5; P is a payload having a structure as shown in formula (i'), wherein the structure as shown in formula (i') is as defined in any one of claims 1 to 7.

20. 【Catalogue 27】 20. The conjugate of claim 19, which is selected from:

Citation Information

Patent Citations

  • Novel Stable Antibody-Drug Conjugates and Their Applications

    JP2017514812A

  • Exatecan Derivatives and Their Linker-Payload and Conjugates

    JP7536188B2

  • Antibody-drug conjugate

    WO2014057687A1

  • Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof

    WO2020063673A1

  • Antibody-drug conjugate and application thereof

    WO2021022678A1